Mycobacterium tuberculosis Infection and Disease

Actualizado Reviewed

Epidemiology

Tuberculosis (TB) is the leading cause of morbidity and mortality among people with HIV worldwide. In 2020 and 2021, progress towards reducing TB morbidity and mortality slowed amidst the widespread disruption of health services from the COVID-19 pandemic. Globally, the annual number of estimated TB deaths increased in 2020 and 2021, to 1.5 million and 1.6 million, respectively.1,2 Among people with HIV, there were an estimated 703,000 people who had TB, but only 52% were diagnosed and reported. A total of 187,000 deaths among people with HIV were attributed to TB in 2021, the first time there has been an increase in HIV-associated TB deaths since 2006.2 People with HIV still account for a disproportionate number of TB deaths worldwide (11.8% of deaths vs. 6.7% of TB cases); however, a 47% reduction in deaths has occurred since 2010.2

In the United States, more than two-thirds (5,456; 71.4%) of people newly reported with TB in 2021 were born outside the United States, similar to 2019 and 2020 proportions.3 The incidence of HIV-related TB in the United States has declined substantially, in part because of the widespread use of antiretroviral therapy (ART).4,5 Among all people reported with TB with known HIV status in the United States in 2021, 293 people (4.2%) were coinfected with HIV (6.3% among people with TB aged 25–44 years vs. 5.6% among those aged 45–64 years).6 Overall, the proportion of reported people with TB and HIV co-infection has been steadily declining over the past decade (7.4% in 2011).

Latent TB Infection

TB infection occurs when a person inhales droplet nuclei containing Mycobacterium tuberculosis organisms. Usually within 2 to 12 weeks after infection, the immune response limits the multiplication of tubercle bacilli. However, viable bacilli can persist for years, a condition referred to as latent TB infection (LTBI). People with LTBI are asymptomatic and are not infectious. TB disease (defined as clinically active disease, often with positive smears and cultures) can develop soon after exposure to M. tuberculosis organisms (primary disease) or after reactivation of latent infection.7,8 The risk of TB disease due to reactivation of LTBI for people with untreated HIV has been estimated as 3% to 16% per year, which approximates the lifetime risk of TB disease for people with LTBI who do not have HIV (approximately 5%).9-14 The risk of TB disease begins in the first year following HIV infection.15 TB disease can occur at any CD4 T lymphocyte (CD4) cell count, although the risk increases with progressive immunodeficiency.15,16 The estimated annual risk of developing TB disease among people with LTBI (diagnosed by a positive tuberculin skin test [TST] or interferon-gamma release assay [IGRA] in the absence of a TB disease diagnosis) is 3 to 12 times greater for people with untreated HIV than for those without HIV.17 Even with effective ART, the risk of TB disease among people with HIV remains greater than that among the general population.18 Since 2006, the TB incidence rate in people with HIV has been lower than in previous years, but the TB risk is still substantially higher than among people without HIV.19 In the United States, the most common predisposing factor for TB infection is birth or residence outside of the United States.20

The risk of progression from LTBI to TB disease in people with HIV is reduced both by ART and by the treatment of LTBI.18,21-24 In combination with ART, isoniazid preventive therapy decreased the risk of TB disease by 76% among people with HIV in Brazil.25 Furthermore, isoniazid preventive therapy and ART independently and additively decreased the risk of death and severe HIV-related illness.21,23

Diagnosing Latent TB Infection

All people with HIV should be evaluated for LTBI at the time of HIV diagnosis, regardless of their epidemiological risk of TB exposure. In programmatic settings in the United States, TB screening has been suboptimal, with only 47% to 69% of people with HIV presenting to care completing initial screening, and 42% of those with LTBI initiating therapy.26-30 The two current diagnostics available for the detection of M. tuberculosis infection in the United States, IGRA and TST, help differentiate those with and without TB infection. However, the diagnostic accuracy of TST and IGRA is limited; a negative test does not exclude the diagnosis of LTBI or TB disease, and a positive test does not, by itself, mean LTBI therapy is warranted. Decisions about medical and public health management should include epidemiological risk factors, medical history, and other clinical information when interpreting IGRA or TST results.

People with advanced HIV (CD4 count <200 cells/mm3) and negative diagnostic tests for LTBI, and no indications for initiating empiric LTBI treatment (i.e., no recent exposure to a culture-confirmed TB case) should be retested for LTBI once they start ART and attain a CD4 count ≥200 cells/mm3 to ensure that the initial test result was a true negative result.31-33 Annual testing for LTBI using TST or IGRA is recommended only for people with HIV who have a history of a negative test for infection and are at high risk for repeated or ongoing exposure to people with active TB disease (e.g., during incarceration, travel to a high-TB incidence country, homelessness, living in a congregate setting).34

Traditionally, LTBI has been defined by the presence of a positive TST (≥5 mm of induration at 48–72 hours in people with HIV) in people with no clinical or radiographic evidence of TB disease. Despite the extensive experience with the TST among people with HIV, the test has several disadvantages: the requirement for two visits to place and read the test, decreased specificity (false positive results) among people who received Bacillus Calmette-Guérin (BCG) vaccination, and decreased sensitivity (false negative results) among people with advanced immunodeficiency.33,35 The first two limitations of the TST have led to broader use of IGRAs for the detection of LTBI.

IGRAs include the T-SPOT.TB and QFT-TB Gold Plus (QFT-Plus). Systematic reviews and meta-analyses, as well as a large study in the United States, have found that IGRAs generally have higher specificity than the TST, may correlate better with exposure to M. tuberculosis, and are less likely to cross-react with BCG vaccination or exposure to nontuberculous mycobacteria.19,36,37 A systematic review among people with HIV did not find robust evidence that IGRAs were superior to TST in diagnosing either active TB or LTBI.33 However, in a prospective study of 1,510 people with HIV in the United States (median CD4 count of 532 cells/mm3), T.SPOT.TB was significantly more specific (99.7%) and had a significantly higher positive predictive value (PPV; 90.0%) than the older QuantiFERON Gold In-Tube (QFT-GIT) (96.5% specificity, 50.7% PPV) and TST (96.8% specificity, 45.4% PPV). QFT-GIT was significantly more sensitive (72.2%) than TST (54.2%) and T.SPOT.TB (51.9%).38

As with the TST, progressive immunodeficiency is associated with decreased sensitivity of IGRAs.39 In addition, the reproducibility of positive results of IGRAs may be limited. Among 46 people with HIV who had initial positive tests with the QFT-GIT assay, 33 (72%) had negative repeat tests, particularly those whose responses were at the lower range of the manufacturer’s suggested range of positive results.40 Similar to recommendations for healthcare workers, annual testing for people with HIV is no longer recommended unless high risk exists for repeated or ongoing exposure to people with active TB disease.41

Among people with HIV, the correlation between the TST and IGRA test results is poor to moderate.42,43 In prospective studies not limited to people with HIV, positive results with either the TST or IGRA were associated with an increased risk of developing TB disease.19,44-46 In some studies (again not limited to people with HIV), patients with a positive IGRA were at a higher risk of subsequently developing TB disease than those with a positive TST.19,47,48 Despite its limitations, a positive TST result strongly predicts that the treatment of LTBI will decrease the risk of TB progression among people with HIV.18 Studies are underway to formally evaluate if IGRAs are similarly predictive.49

Although no definitive comparisons of the TST and IGRAs for screening people with HIV in low-burden settings have been published, both the TST and the approved IGRAs are considered appropriate for TB screening among people with HIV in the United States.17,38 Some experts have suggested using both the TST and an IGRA in a stepwise or sequential manner to screen for LTBI, but the predictive value of this approach is not clear, and it may be challenging to implement. The routine use of both TST and IGRAs in a single patient to screen for LTBI is not recommended in the United States.50

As tests of immune reactivity against M. tuberculosis, TST and IGRAs are often positive among people with TB disease. Therefore, all people with a positive TST or IGRA should be evaluated for the possibility of active TB disease.17 Most, but not all, people with HIV and TB disease have symptoms (e.g., cough, fever, sweats, weight loss, lymphadenopathy); the absence of these symptoms had a 98% negative predictive value for culture-positive TB in low-resource settings, although this varied depending on pretest probability.51 The addition of a chest radiograph improved the sensitivity of this screening algorithm but decreased specificity.52 It is important to note that in a symptomatic patient with clinical suspicion of TB disease, a negative TST or IGRA does not rule out TB disease, particularly in those with CD4 count <200 cells/mm3.

Obtaining a sputum specimen for M. tuberculosis identification is the gold standard for diagnosing pulmonary TB disease, but it is not high yield in screening people with HIV without pulmonary symptoms, particularly in low-prevalence settings. Therefore, a negative symptom screen (including absent cough of any duration) coupled with a normal chest radiograph is usually sufficient to exclude TB disease in a patient with a positive TST or IGRA in low TB incidence settings.17 Sub-clinical TB among people with HIV is of greater concern in high TB burden settings.53

Treating Latent TB Infection

Recommendations for Treating LTBI to Prevent TB Disease in People with HIV

Indications

  • Positive screening testa for LTBI (≥5 mm of induration at 48–72 hours in people with HIV or positive IGRA) regardless of BCG status, no evidence of active TB disease, and no prior history of treatment for active disease or latent TB infection (AI).
  • Close contact with a person with infectious TB (such as someone who has shared air space, such as in a household or close congregate setting, with a person with active pulmonary TB according to the Centers for Disease Control and Prevention Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis) regardless of screening test result and CD4 count (AII).

Preferred Therapy

  • Isoniazid 15 mg/kg PO once weekly (900 mg maximum) plus rifapentine (see weight-based dosing below) PO once weekly plus pyridoxine 50 mg PO once weekly (3HP) for 12 weeks (AI). Note: 3HP is recommended only for virally-suppressed patients receiving an efavirenz-, raltegravir-, or once-daily dolutegravir-based ARV regimen (AII).
    • Rifapentine Weekly Dose (maximum 900 mg)
      • Weighing 25.132 kg: 600 mg
      • Weighing 32.1–49.9 kg: 750 mg
      • Weighing ≥50.0 kg: 900 mg
  • Isoniazid 300 mg PO daily plus rifampin 600 mg PO daily plus pyridoxine 25–50 mg PO daily (AI) for 3 months (3HR). See the Dosing Recommendations for use of ARV and Anti-TB Drugs When Treating Latent TB table for the list of ARV drugs not recommended for use with rifampin (e.g., protease inhibitors, bictegravir) and those which require dosage adjustment (i.e., raltegravir, dolutegravir, or maraviroc).

Alternative Therapy

  • Isoniazid 300 mg PO daily plus pyridoxine 25–50 mg PO daily for 6–9 months (AII) or
  • Rifampin 600 mg PO daily for 4 months (BI) (4R)
  • Isoniazid 300 mg PO daily plus rifapentine (see weight-based dosing below) PO daily plus pyridoxine 25–50 mg PO daily for 4 weeks (BI) (1HP) Note: 1HP is recommended only for patients receiving an efavirenz-based ARV regimen (AI).
    • Rifapentine Daily Dose (maximum 600 mg)
      • Weighing <35 kg: 300 mg
      • Weighing 35–45 kg: 450 mg
      • Weighing >45 kg: 600 mg
  • For people exposed to drug-resistant TB, select drugs for prevention of TB after consultation with experts and with public health authorities (AIII).

Pregnancy Considerations

  • 4R and 3HR are acceptable alternative regimens for pregnant people with HIV (BIII).
  • For pregnant people receiving effective ART and without close household contact with infectious TB or recent test for TB infection (TST or IGRA) conversion from negative to positive, therapy for LTBI may be deferred until after delivery (BIII).
  • Although rifampin generally is considered safe in pregnancy, data on the use of rifapentine are extremely limited and its use in pregnant people is not currently recommended (BIII).

Additional Considerations

  • Deferring ART until after completion of treatment for LTBI is not recommended (AI).
  • Given the important drug–drug interactions between rifamycins and several antiretroviral (ARV) agents, selection of an LTBI regimen will depend on a patient’s current or planned ARV regimen.
a Screening tests for LTBI include a tuberculin skin test (TST) or interferon-gamma release assay (IGRA); see text for details regarding these tests.

Key: H = Isoniazid; P = Rifapentine; R = Rifampin; ARV = antiretroviral; CDC = Centers for Disease Control and Prevention; CD4 = CD4 T lymphocyte; CNS = central nervous system; DOT = directly observed therapy; IRIS = immune reconstitution inflammatory syndrome; IPT = isoniazid preventive therapy; LTBI = latent tuberculosis infection; PI = protease inhibitor; PO = orally; TB = tuberculosis

Once active TB disease is excluded and in the absence of other medical contraindications, people with HIV with a positive TB screening test should receive LTBI treatment (AI), unless there is documentation of prior treatment for active TB or LTBI.54 Additionally, people with HIV who are in close contact with anyone with infectious TB should receive LTBI treatment, regardless of their TB screening test results and CD4 count (AII). Selection of an LTBI regimen may depend on the potential for drug interactions, toxicity concerns, as well as medication availability and/or cost (see Recommendations for Treating LTBI to Prevent TB Disease in People with HIV table above). People with HIV who have been treated successfully for LTBI should not have repeat testing with TST or IGRA; a previously positive test result generally will not revert to negative.

People with HIV in the United States who have a negative TST or IGRA and no recent contact with a person with infectious TB likely will not benefit from the treatment of LTBI, and preventive therapy is not generally recommended (AIII); this is in contrast to high TB prevalence countries where isoniazid (i.e., isoniazid preventive therapy; IPT) decreased TB risk and mortality in people with HIV, regardless of TST or IGRA result.24

LTBI treatment and ART act independently to decrease the risk of TB disease.22,23,25,55,56 Therefore, the use of both interventions is recommended for people with LTBI and HIV (AI). Given the important drug–drug interactions between rifamycins and several antiretroviral (ARV) agents, selection of an LTBI regimen will depend on a patient’s current or planned ARV regimen. Deferring ART until after completion of treatment for LTBI is not recommended (AI).23

Preferred Drugs for Treatment of Latent TB Infection

3HP
  • Rifapentine (weight-based dosing) orally (PO) once weekly plus isoniazid 15 mg/kg PO once weekly (900 mg maximum) plus pyridoxine 50 mg PO once weekly for 12 weeks is one of two preferred regimens for the treatment of LTBI (AI).54

In two randomized controlled trials, rifapentine plus isoniazid once weekly for 12 weeks (3HP) was as effective and well-tolerated as 6 to 9 months of daily isoniazid, including in people with HIV whose CD4 counts were generally >350 cells/mm3 and who were not yet on ART.57,58 3HP treatment completion rates with self-administered therapy were inferior to those with directly observed therapy (DOT) but non-inferior among study participants enrolled in the United States—and generally high overall.59

Although individuals taking ART were not included in the Phase 3 trial of 3HP,57 the pharmacokinetic (PK) profile of efavirenz with daily rifapentine and isoniazid is favorable.60,61 Raltegravir concentrations were modestly increased when it was given with once-weekly rifapentine in healthy volunteers.62 In a Phase 1/2 single-arm study of people with HIV treated with dolutegravir and 3HP, rifapentine decreased dolutegravir exposure by 26%. However, trough concentrations remained above the 90% maximum inhibitory concentration for all but one participant, and all participants maintained an undetectable viral load throughout the study period.63 Based on these PK data and limited outcome data, 3HP is recommended in virally suppressed people receiving efavirenz, raltegravir, or once-daily dolutegravir without dose adjustment of rifapentine, isoniazid, or ART (AII).64 A trial is currently underway examining the use of 3HP in ART-naive participants who are initiating therapy with a dolutegravir-based regimen.65 3HP has not been studied in patients receiving twice-daily dolutegravir and is therefore not recommended (AIII).

3HR
  • Daily isoniazid 300 mg PO daily plus rifampin 600 mg PO daily plus pyridoxine 25 mg to -50 mg PO daily for 3 months is also a preferred option for treatment of LTBI in people with HIV (AI).

In studies of adults and children without HIV who had a positive TST, those who received 3HR had a similar decreased risk of TB disease, hepatotoxicity, and adverse effects requiring treatment discontinuation compared with those who received ≥6 months of daily isoniazid.66-70 Among people with HIV, several studies found no difference in the incidence of TB disease between those who received 3HR and those who received ≥6 months of daily isoniazid, regardless of TST status;71-74 hepatotoxicity was less frequent among those receiving 3HR, but treatment-limiting adverse effects were more common.54 When using rifampin for LTBI treatment, either dose adjustment or substitution of many commonly used ARVs may be needed (see Dosing Recommendations for Use of ARV and Anti-TB Drugs When Treating Latent TB table).

Alternative Drugs for Treatment of Latent TB Infection

Isoniazid
  • Isoniazid 300 mg PO daily plus pyridoxine 25 mg to 50 mg PO daily for 6 to 9 months is an alternative regimen for the treatment of LTBI, particularly when drug–drug interactions between rifamycins and ARV regimens limit the use of rifamycin-containing LTBI therapies (AII).

Daily isoniazid for 6 to 9 months is effective and reasonably well-tolerated; severe toxicity is infrequent.23,74-78 However, treatment completion rates are suboptimal, decreasing its effectiveness.79 Longer courses of isoniazid (e.g., 12 months) are more effective at preventing TB but carry a higher risk of toxicity80,81 and patients are more likely to complete shorter regimens.57,59,79,82-85 Peripheral neuropathy, hepatitis, and rash may be caused by either isoniazid or some ARV drugs. Isoniazid, when used, should be supplemented with pyridoxine at a dose of 25 to 50 mg per day to prevent peripheral neuropathy (AIII).

4R
  • Rifampin 600 mg PO daily for 4 months (4R) is an alternative regimen for the treatment of LTBI in people with HIV (BI).

A large trial compared 4 months of daily rifampin (4R) to 9 months of daily isoniazid (9H) in more than 6,000 participants who were predominantly HIV-seronegative.77 Although rates of incident active TB were low in both arms, the 4R regimen was non-inferior to 9H. Treatment completion rates were significantly higher and adverse events were less common in the 4R arm than in the 9H arm (78.8% vs. 63.2%; P < 0.001 and 1.5% vs. 2.6%; P = 0.003, respectively). However, only 255 participants were people with HIV, which limits the generalizability of the findings for this population. Although the National Tuberculosis Controllers Association (NTCA)/CDC guidelines recommend 4R as a preferred treatment for LTBI in people without HIV,54 given the lack of trial data in people with HIV, the 4R regimen is recommended only as an alternative to 3HP, 3HR, and 6 or 9 months of isoniazid in people with HIV (BI). When using rifampin for LTBI treatment, either dose adjustment or substitution of key ARVs may be needed. Given the theoretical but unproven risk of selecting for drug-resistant TB with rifamycin monotherapy in undiagnosed early-stage TB disease and the relatively poor performance of symptom screens alone in people with HIV on ART,86,87 some clinicians would obtain a specimen for M. tuberculosis testing before starting 4R for LTBI. Due to limited data on 4R in people with HIV, concerns about using this regimen in people with low CD4 cell counts, and an absence of data on the use of 4 months of rifabutin either in people with or without HIV, rifabutin monotherapy is not recommended (AIII).88-90

1HP
  • Isoniazid 300 mg PO daily plus rifapentine (weight-based dosing to a maximum of 600 mg) PO daily plus pyridoxine 25 mg to 50 mg PO daily for 4 weeks (1HP) is an alternative therapy for the treatment of LTBI in people with HIV treated with efavirenz (BI).

The BRIEF-TB study (AIDS Clinical Trials Group [ACTG] 5279) evaluated 1 month of daily rifapentine plus isoniazid (1HP) versus 9 months of daily isoniazid (9H) in people with HIV residing in mostly high TB burden settings (TB incidence >60 per 100,000 population).83 The median CD4 count of study participants was 470 cells/mm3, 50% of the study population was on efavirenz or nevirapine-based ART regimens at study entry, and 21% of the study population was TST positive. 1HP was non-inferior to 9H when comparing the composite outcome of confirmed or probable TB, death due to TB, and death due to unknown cause. Treatment completion rates (by self-report) were 97% in the 1HP arm and 90% in the 9H arm. Of note, although the population of people with HIV enrolled was at increased risk for LTBI due to high endemic exposure, the number of participants with documented LTBI based on TST or IGRA testing was low (23%), and the overall event rate (i.e., the number of participants who developed active TB in either arm) was also low (0.56/100 person-years) after more than 3 years of follow-up. Based on these data, 1HP is recommended as an alternative regimen for treatment of LTBI in people with HIV (BI). The NTCA/CDC guidelines do not include 1HP as a preferred or alternative regimen given that the BRIEF-TB study was performed largely in people with HIV living in high TB burden settings, most of whom did not have positive tests for LTBI.54 In light of the strengths of the study results and the convenience and safety of the regimen, some clinicians may choose to use 1HP for treatment of LTBI as an alternative option to those recommended in the current NTCA/CDC guidelines. If ART is administered together with 1HP, an efavirenz-based regimen should be used (AI).60,91 A study evaluating co-administration of 1HP with dolutegravir is in progress; the use of dolutegravir-based ART should await results from this trial.92

Dosing Recommendations for Use of ARV and Anti-TB Drugs When Treating Latent TB Infection
TB DrugARV DrugsDose of TB Drug
Isoniazid (INH)
  • All ARVs
  • Note: for information on coadministration of ARVs with rifampin or rifapentine, see entries below

Use INH with pyridoxine 25–50 mg PO daily (50 mg once weekly if used with 3HP)

For 3HP (weekly INH + rifapentine x 12 weeks)

  • 15 mg/kg PO once weekly (900 mg maximum)

For 3HR (daily INH + rifampin x 3 months), or 1HP (daily INH + rifapentine x 4 weeks), or INH alone (daily INH x 69 months)

  • 300 mg PO daily
Rifampina
  • NRTIs (TAF with cautionb)
  • EFV 600 mg
  • DTG, RAL (twice daily), and MVC without a strong CYP3A4 inhibitor (note: doses of these ARV drugs need to be adjusted when used with rifampin)
  • IBA, T-20

For 3HR (daily rifampin + INH x 3 months), or 4R (daily rifampin x 4 months)

  • 600 mg PO daily
  • All other ARVs
Not recommended

Rifapentinea 3HP

Weekly rifapentine + INH x 12 weeks

  • EFV 600 mg, RAL or once daily DTG
  • NRTIs (TAF with cautionb)
  • IBA, T-20
  • Weighing 32.1–49.9 kg: 750 mg PO weekly
  • Weighing ≥50.0 kg: 900 mg PO weekly
  • All other ARVs
Not recommended

Rifapentinea 1HP

Daily rifapentine + INH x 4 weeks

  • NRTIs (TAF with cautionb)
  • EFV 600 mg
  • IBA, T-20
  • Weighing <35 kg: 300 mg PO daily
  • Weighing 35–45 kg: 450 mg PO daily
  • Weighing >45 kg: 600 mg PO daily
  • All other ARVs
Not recommended
a For additional drug—drug interaction information between antiretrovirals and anti-TB drugs, see Drug-Drug Interactions in the Adult and Adolescent Antiretroviral Guidelines.

b If TAF and rifamycins are coadministered, monitor for HIV treatment efficacy. Note that FDA labeling recommends not to coadminister. See Drug-Drug Interactions in the Treatment of HIV-Related TB below and Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections table for more information

Key: ARV = antiretroviral; BIC = bictegravir; DTG = dolutegravir; EFV = efavirenz; IBA = ibalizumab; IM = intramuscular; INH = isoniazid; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; PO = oral; RAL = raltegravir; RTV = ritonavir; T-20 = enfuvirtide; TAF = tenofovir alafenamide; TB = tuberculosis

Treatment of LTBI Following Exposure to Drug-Resistant TB

For people exposed to drug-resistant TB, a regimen for LTBI should be selected after consultation with experts or with public health authorities (AIII).93 A large randomized clinical trial of 26 weeks of either isoniazid or delamanid for people at high risk for TB, including people with HIV, following household exposure to drug-resistant TB is in progress.94

Monitoring for Adverse Events Related to Treating Latent TB Infection

Individuals receiving TB-preventive therapy should be evaluated by a clinician monthly to assess adherence and evaluate for possible drug toxicity. Although people with HIV may not have a higher risk of hepatitis from isoniazid than people without HIV, people with HIV should have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and total bilirubin levels measured before starting LTBI treatment and repeated if abnormal.54 People with concomitant chronic viral hepatitis and older individuals have an increased risk of isoniazid-related hepatotoxicity, and such people should be monitored closely when being treated for LTBI.95,96

Following initiation of isoniazid, ALT and AST levels often increase during the first 3 months of treatment but return to normal despite continued therapy. Hepatotoxicity also can occur with rifamycins, although it is less common than with isoniazid.78,83 Factors that increase the risk of drug-induced clinical hepatitis include daily alcohol consumption, underlying liver disease, pregnancy and early postpartum, and concurrent treatment with other hepatotoxic drugs.97 At each visit, patients should be asked about adherence, new medications, and alcohol use and should be screened for potential adverse effects of treatment for LTBI (e.g., unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesia of the hands and feet, persistent fatigue, weakness or fever lasting 3 or more days, abdominal tenderness, easy bruising or bleeding, arthralgia) and told to stop medications immediately and return to the clinic for an assessment should any of these occur (AIII).

If the serum ALT or AST levels increase to (1) greater than five times the upper limit of normal without symptoms or (2) greater than three times the upper limit of normal AND total bilirubin greater than two times the upper limit of normal without symptoms or (3) greater than three times the upper limit of normal with symptoms (or greater than two times the baseline value for patients with baseline abnormal transaminases), LTBI treatment should be stopped (AIII).

The ultimate decision regarding resumption of therapy with the same or different agents for LTBI treatment should be made after weighing the risk for additional hepatic injury against the benefit of preventing progression to TB disease,97 and ideally in consultation with an expert in treating LTBI in people with HIV. If a local expert is not available through the public health department, clinicians and TB programs can contact the CDC (tbinfo@cdc.gov) and utilize remote TB medical consultation services available through the CDC-funded TB Center of Excellence that serves their region.

Clinical Manifestations of TB Disease

Similar to people without HIV, people with HIV and TB disease may be asymptomatic but have positive sputum cultures with or without abnormal findings on chest radiograph (subclinical TB).98,99 In ambulatory people with HIV, the presence of any one of the classic symptoms of TB disease (i.e., cough, fever, night sweats, weight loss) has high sensitivity but low specificity for diagnosing TB as assessed in resource-limited settings.51 Compared to treatment-naive patients with HIV, the sensitivity of classic TB symptoms is lower in people with HIV on ART.86

The presentation of TB disease is influenced by the degree of immunodeficiency.100-102 In people with HIV and CD4 counts >200 cells/mm3, HIV-related TB generally resembles TB among people without HIV. Most people with or without HIV have disease limited to the lungs, and common chest radiographic manifestations are upper lobe infiltrates with or without cavitation.103

In people with HIV and CD4 counts <200 cells/mm3, the chest radiographic findings of pulmonary TB are markedly different, with infiltrates showing no predilection for the upper lobes, and cavitation uncommon.100,103,104 Normal chest radiographs can be seen in some people with respiratory symptoms and positive sputum cultures. Thoracic CT scans may demonstrate mild reticulonodular infiltrates despite a normal chest radiograph.105

With increasing degrees of immunodeficiency, extrapulmonary (especially lymphadenitis, pleuritis, pericarditis, and meningitis) or disseminated TB are more common. In people with HIV who are markedly immune-suppressed, TB can be a severe systemic disease with high fevers, rapid progression, and features of sepsis.106 Clinical manifestations of extrapulmonary TB in people with HIV are not substantially different from those described in people without HIV. TB must be considered in disease processes involving any site in the body,107 especially in those with central nervous system (CNS) disease, when early TB treatment is essential to improve outcomes.108-111

After initiation of ART, immune reconstitution can unmask subclinical TB disease, resulting in pronounced inflammatory reactions at the sites of infection (see Unmasking TB-IRIS below).

Diagnosis

Initial diagnostic testing for TB disease should be directed at the anatomic site of symptoms or signs (e.g., lungs, lymph nodes, urine, cerebrospinal fluid).17 Pulmonary involvement is common at all CD4 counts.99,112 The initial evaluation of a person suspected of having HIV-related TB should always include chest imaging, even in the absence of pulmonary symptoms or signs. However, chest radiography is an imperfect screen for pulmonary TB, particularly among individuals with advanced immunodeficiency who can have TB culture-positive sputum despite normal chest radiographs.113,114 Therefore, sputum acid-fast bacilli (AFB) smear, nucleic acid amplification (NAA) testing, and AFB culture should be performed in people with HIV with symptoms of TB disease who have a normal chest radiograph, as well as in those with no pulmonary symptoms but evidence of TB disease elsewhere in the body.17

Sputum culture yield is not affected by HIV or the degree of immunodeficiency. Sputum smear-negative, culture-positive TB disease is common among people with HIV, particularly those with advanced immunodeficiency and non-cavitary disease.115,116 NAA tests have a higher sensitivity for culture-positive disease than smear.17,117 Smear and culture of three sputum specimens is recommended based on a large study in people with HIV that showed a 10% incremental yield for broth culture between the second and third specimens.118 Additionally, up-front NAA testing for M. tuberculosis can expedite diagnosis.17

Lymph node involvement is common in HIV-related TB, and the combined yield of histopathology, smear, and culture from needle aspirates of enlarged lymph nodes is quite high.119,120 While NAA testing on specimens other than sputum is an off-label use of the test, a positive NAA test result can be useful as evidence of extrapulmonary TB and for clinical decision-making.121 Histopathologic findings also are affected by the degree of immunodeficiency. People with relatively intact immune function have typical granulomatous inflammation associated with TB disease. With progressive immunodeficiency, granulomas become poorly formed or can be completely absent.101,122

Pleural fluid, pericardial fluid, ascites, and cerebrospinal fluid should be sampled if there is clinical evidence of involvement. Polymerase chain reaction (PCR) testing to aid with molecular identification of M. tuberculosis on formalin-fixed tissue is available through reference laboratories and, in special situations, through the CDC. Clinical providers and pathologists should contact their state or local health department for consultation with the CDC (tbinfo@cdc.gov) and the CDC-funded TB Center of Excellence for assistance with referring specimens for evaluation. The yield of mycobacterial urine and blood cultures depends on the clinical setting; among people with HIV and advanced immunodeficiency, the yield of culture from these two readily available body fluids can be relatively high101,107 and may allow definitive diagnosis and be the only source of an isolate for drug-susceptibility testing (DST).123

Nucleic-Acid Amplification Testing

NAA tests provide rapid diagnosis of TB, and some assays also provide rapid detection of drug resistance. NAA assays, if positive, are highly predictive of TB disease when performed on Acid-Fast Bacillus (AFB) smear-positive specimens. However, because nontuberculous mycobacterial infections (NTM) may occur in people with HIV with advanced immunodeficiency, negative NAA results in the setting of smear-positive specimens may indicate NTM infection and can be used to direct further workup and guide decisions about the need for respiratory isolation.

NAA tests are more sensitive than AFB smears, being positive in 50% to 80% of smear-negative, culture-positive sputum specimens124,125 and up to 90% when three NAA tests are performed. Therefore, it is recommended that for all patients with suspected pulmonary TB, an NAA test be performed on at least one sputum specimen.17,126 NAA tests also can be used on extrapulmonary specimens with the caveat that the sensitivity is often lower than with sputum specimens.17 Importantly, a smear-negative specimen with a negative NAA test result does not rule out active TB disease.

The Xpert MTB/RIF assay is an automated NAA test that can detect both M. tuberculosis and mutations in the rpoB gene associated with rifampin resistance. It has been implemented widely in resource-limited settings with high TB prevalence and as a frontline TB diagnostic test in people with HIV.127 This assay combines simple processing requirements in the laboratory and rapid turnaround (results within 2 hours). In a meta-analysis, the overall sensitivity and specificity of the Xpert MTB/RIF assay were 88% (95% confidence interval [CI], 83% to 92%) and 98% (95% CI, 97% to 99%), respectively. The assay is somewhat less sensitive among people with HIV overall,128 however, this may be, in part, attributed to a higher prevalence of smear-negative disease in people with HIV.129 In one key study from South Africa, the sensitivity of Xpert MTB/RIF a relationship with CD4 count was demonstrated, indicating higher sensitivity among people with HIV as the CD4 count declined below 500 cells/mm3.130 Importantly, patients in this study with the lowest CD4 count (<100 cells/mm3) actually had higher rates of smear-positivity and higher markers of severe TB disease (C-reactive protein, anemia, and WHO symptom screen).

Xpert MTB/RIF sensitivity in extrapulmonary specimens is up to 95% in smear-positive specimens and 69% in smear-negative specimens.131 Median sensitivity varied by specimen type, with higher yield from lymph nodes (96%), cerebrospinal fluid (85%), and gastric aspirates (78%) and lower yield from pleural fluid (34%) and other non-pleural serous fluids (67%). Xpert MTB/RIF also has been applied with excellent diagnostic accuracy to stool specimens in people with pulmonary TB,132 which may provide an alternative for people with HIV who are being evaluated for TB and unable to expectorate.

The next-generation Xpert MTB/RIF Ultra improved the sensitivity of the existing test platform, but it is not currently approved by the U.S. Food and Drug Administration (FDA) or available in the United States. Similarly, the Xpert MTB/XDR cartridge incorporates other drug-resistance targets that may be relevant for constructing a treatment regimen for drug-resistant TB, particularly in settings without access to conventional growth-based or sequencing-based DST, but is also not currently approved by the U.S. FDA and is unavailable in the United States (see Drug-Resistance Testing, below).133

Lipoarabinomannan (LAM)

LAM is an M. tuberculosis cell wall polysaccharide that can be detected in the urine of people with TB.134-137 LAM has been shown to be more sensitive and specific as an adjunct diagnostic test in people with HIV with advanced immunosuppression. The Alere Determine TB LAM is a lateral flow strip applied to a urine sample and recommended by the WHO as an additional diagnostic test for TB among people with HIV.138 Newer generation LAM assays have increased sensitivity and may be particularly useful in paucibacillary clinical specimens such as cerebrospinal fluid. In a study of 101 patients with suspected TB meningitis, 95 of whom were people with HIV, the SILVAMP TB LAM (Fujifilm) sensitivity from cerebrospinal fluid was 52% for definite or probable TB meningitis (with specificity of 98%), which compared favorably to the sensitivity of 55% for Xpert Ultra. LAM assays are not commercially available in the United States at this time.139

Drug-Resistance Testing

Evaluation for TB drug resistance should be considered in all people with HIV, especially those who meet any of the following criteria:

  • Known exposure to a person with drug-resistant TB,
  • Residence in a setting with high rates of primary drug-resistant TB,
  • Persistently positive smear or culture results at or after 4 months of treatment, or
  • Previous TB treatment, particularly if it was not directly observed or was interrupted for any reason.

Rapid molecular DST for rifampin (and isoniazid, if available) should be performed on the initial isolates from all patients suspected of having TB, because resistance to rifampin is associated with an increased risk of treatment failure, recurrent TB, and amplification of resistance to additional TB medications.140,141

The presence of multidrug-resistant TB (MDR TB; defined as resistance to at least isoniazid and rifampin) or extensively drug-resistant TB (XDR TB; defined as MDR TB with additional resistance to a fluoroquinolone and either bedaquiline or linezolid) is associated with a markedly increased risk of death.142-144 Therefore, early identification of drug resistance, with appropriate adjustment of the treatment regimen based on both full molecular and conventional DST results, is critical to the successful treatment of TB disease and to curbing transmission of drug-resistant M. tuberculosis.17

For all patients with TB disease, phenotypic DST to first-line TB drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) should be performed, regardless of the source of the specimen. Given the alternative of a shorter drug-susceptible TB regimen containing moxifloxacin (see Treating TB Disease), public health laboratories in the U.S. may add routine moxifloxacin susceptibility testing as well. Molecular resistance testing should be performed, and resistance testing should be repeated if sputum cultures remain positive for M. tuberculosis at or after 4 months of treatment or become positive again 1 month or longer after culture conversion to negative. Resistance testing for second-line TB medications (including bedaquiline, linezolid, clofazimine, pretomanid, cycloserine, ethionamide, and others) should be limited to specimens with resistance to first-line TB medications and should be performed in reference laboratories with substantial experience in these techniques.126

Conventional Growth-Based Drug-Susceptibility Testing

Conventional DST is used widely and has been validated for first-line drugs. The disadvantage of this technique, however, is that the combined turnaround time of a conventional broth or agar-based culture followed by DST may be as long as 8 weeks,145 due to the slow growth of M. tuberculosis. During this time, people with drug-resistant TB may be receiving ineffective, empiric first-line TB therapy, which could allow ongoing transmission, further clinical deterioration, acquisition of additional drug resistance, and death, particularly in individuals with HIV.144 Yet, for many second-line drugs used to treat MDR and XDR TB, conventional DST remains either the gold standard or the only available technique because molecular correlates of phenotypic drug resistance are incomplete.

Molecular Tests for Drug Resistance

Genotypic testing to identify mutations that confer drug resistance allows rapid detection of resistance. The relationship between these mutations and drug resistance has been studied for a number of TB medications.146,147 Commercial NAA tests—such as Xpert MTB/RIF—identify resistance mutations associated with rifampin, and commercially available line probe assays (LPAs) identify genotypic resistance to other drugs.129,148 All probe-based assays, including Xpert MTB/RIF and LPAs, should be confirmed with sequence-based tests and growth-based DST. For initial evaluation of drug resistance or confirmation of drug resistance identified by the aforementioned assays, the CDC Division of Tuberculosis Elimination has a Molecular Detection of Drug Resistance (MDDR) service that offers rapid sequencing-based testing for first-and second-line TB medications at no charge for providers evaluating people for drug-resistant TB. State TB programs and state laboratories also should be consulted for resistance testing options. Several assays can be performed on cultured isolates or directly on sputum specimens. Molecular resistance testing also can be performed on extrapulmonary specimens that are NAA-positive; if unable to be performed by local or state public health laboratories, this testing can be arranged through the CDC’s Division of TB Elimination Laboratory (TBLab@cdc.gov).

In low TB prevalence settings—such as the United States—the positive predictive value for NAA tests of rifampin resistance is low.149 False-positive rifampin resistance on Xpert MTB/RIF is associated with lower sputum bacillary burden (i.e., high cycle thresholds on Xpert).150 Therefore, isolates with an initial reading of rifampin resistance by commercial NAA test should always undergo confirmatory testing (rpoB gene sequencing and phenotypic DST), with results taken into consideration for treatment decisions. Clinicians who suspect drug-resistant TB in a patient with HIV should make every effort to expedite a diagnosis and consult with their state TB program and then the CDC as needed.

Treating TB Disease

Treating Active TB Disease in People with HIV
For Drug-Susceptible TB

Preferred Therapy

Intensive Phase (8 weeks)

  • Isoniazid plus pyridoxine plus (rifampin or rifabutin) plus pyrazinamide plus ethambutol 25–50 mg PO daily (AI)
  • If molecular or phenotypic drug susceptibility reports show sensitivity to isoniazid and rifampin, then ethambutol may be discontinued before the end of 8 weeks (AI).

Continuation Phase (for Drug-Susceptible TB)

  • Isoniazid plus pyridoxine plus (rifampin or rifabutin) 25–50 mg PO daily (AII)

Total Duration of Therapy

  • Pulmonary, drug-susceptible, uncomplicated TB: 6 months (BII)
  • Pulmonary TB and positive culture at 8 weeks of TB treatment, severe cavitary disease or disseminated extrapulmonary TB: 9 months (BII)
  • Extrapulmonary TB with TB meningitis: 9–12 months (BII)
  • Extrapulmonary TB in other sites: 6 months (BII)

Alternative Therapy (only for patients receiving an efavirenz-based ARV regimen; not recommended for extrapulmonary TB)

Intensive Phase (8 weeks)

  • Isoniazid plus pyridoxine plus rifapentine 1,200 mg plus moxifloxacin 400 mg plus pyrazinamide 25–50 mg PO daily (AI).a

Continuation Phase (9 weeks)

  • Isoniazid plus pyridoxine plus rifapentine 1,200 mg plus moxifloxacin 400 mg 25–50 mg PO daily (AI).
For Drug-Resistant TB

Empiric Therapy for Suspected Resistance to Rifamycin With or Without Resistance to Other Drugs

  • Isoniazidb plus pyrazinamide plus ethambutol plus (moxifloxacin or levofloxacin) plus (linezolid or amikacinc) (BII)

Resistant to Isoniazid

  • (Moxifloxacin or levofloxacin) plus (rifampin or rifabutin) plus ethambutol plus pyrazinamide for 6 months (BII)

Resistant to Rifamycins With or Without Other Antimycobacterial Agents

Preferred Therapy

  • For 14 days: pretomanid 200 mg plus linezolid 600 mg plus moxifloxacin 400 mg plus bedaquiline 400 PO daily, followed by
  • For 24 weeks: pretomanid 200 mg plus linezolid 600 mg plus moxifloxacin 400 mg daily, and bedaquiline 200 mg PO three times per week
  • Note: Omit moxifloxacin if resistant to fluoroquinolones (AI).

Alternative Therapy

  • An individualized regimen including based on drug susceptibility test results and clinical and microbiological responses, to include ≥5 active drugs, and with close consultation with experienced specialists (BIII).

Duration

6–24 months (see Managing Drug-Resistant TB section below for discussion of treatment duration)

Treatment of TB for Pregnant People 
  • TB therapy should not be withheld because of pregnancy (AIII).
  • Treatment of TB disease for pregnant people should be the same as for nonpregnant people, but with attention to the following considerations (AIII):
    • Monthly monitoring of liver transaminases during pregnancy and the postpartum period is recommended (BIII).
    • If pyrazinamide is not included in the initial treatment regimen, the minimum duration of TB therapy with isoniazid, rifampin, and ethambutol should be 9 months for drug-susceptible TB (AII). The decision regarding whether to include pyrazinamide in treatment regimens for a pregnant person should be made after consultation among obstetricians, TB specialists, and the patient, while considering gestational age and likely susceptibility pattern of the TB strain.
    • Fluoroquinolones are typically not recommended for pregnant people because arthropathy has been noted in immature animals exposed to fluoroquinolones in utero (CIII). Fluoroquinolones can, however, be used in pregnancy for drug-resistant TB if they are required on the basis of susceptibility testing (BII).
    • Based on data derived from studies of streptomycin and kanamycin, and the theoretical risk of ototoxicity with in utero exposure to amikacin, aminoglycosides should be avoided during pregnancy, if possible (AIII).
TB-Associated IRIS

Preventing Paradoxical TB-IRIS

  • In high-risk patients (i.e., starting ART within 30 days after TB treatment initiation and a CD4 count ≤100/mm3) who are responding well to TB therapy and who do not have rifampin resistance, Kaposi sarcoma, or active hepatitis B (BI): prednisone 40 mg/day for 2 weeks, then 20 mg/day for 2 weeks

Managing Paradoxical TB-IRIS

  • Paradoxical reaction/IRIS that is not severe may be treated symptomatically (CIII).
  • For moderately severe paradoxical TB-IRIS, use of prednisone is recommended (AI).
  • In patients on a rifampin-based regimen: prednisone 1.5 mg/kg/day for 2 weeks, then 0.75 mg/kg/day for 2 weeks
  • In patients on a rifabutin plus boosted PI-based regimen: prednisone 1.0 mg/kg/day for 2 weeks, then 0.5 mg/kg/day for 2 weeks
  • Taper over 4 weeks (or longer) based on clinical symptoms; a more gradual tapering schedule over 2 to 3 months is recommended for patients whose signs and symptoms have not improved or have worsened due to tapering (BIII).
Other Considerations in TB Management
  • Adjunctive corticosteroid is recommended for patients with HIV-related TB involving the CNS (AII).
  • Dexamethasone has been used for CNS disease with the following dosing schedule: 0.3–0.4 mg/kg/day for 2–4 weeks, then taper by 0.1 mg/kg per week until 0.1 mg/kg, then 4 mg per day and taper by 1 mg/week; total duration of 12 weeksd
  • Despite the potential of drug–drug interactions, rifamycins remain the most potent TB drug and should remain as part of the TB regimen, unless a rifamycin-resistant isolate is detected or the patient has a severe adverse effect that is likely due to the rifamycin (please refer to the Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB below and the Tuberculosis/HIV Coinfection section of the Adult and Adolescent Antiretroviral Guidelines for dosing recommendations involving concomitant use of rifampin or rifabutin and different ARV drugs).
  • Intermittent rifamycin use can result in the development of resistance in patients with HIV and is not recommended (AI).
a This regimen was not studied and is not recommended for people who are pregnant, breastfeeding, <40kg, or who have most types of extrapulmonary TB (other than pleural TB or lymphadenitis).

b Many patients with rifampin resistance also have resistance to isoniazid. Susceptibility should be confirmed in any patient with rifampin resistance to determine if isoniazid can be included in the treatment regimen.

c Given the risk of ototoxicity and nephrotoxicity with aminoglycosides, use of amikacin should generally be restricted to bridging regimens, while awaiting availability of less toxic medications and/or results of drug-susceptibility testing.

d At doses above 16 mg, dexamethasone is a CYP3A4 inducer and can decrease certain ARVs that are substrates of CYP3A4 (e.g., DOR, RPV, and protease inhibitors). Consultation with a pharmacist is recommended.

Key: ARV = antiretroviral; CNS = central nervous system; DOT = directly observed therapy; IRIS = immune reconstitution inflammatory syndrome; LTBI = latent tuberculosis infection; PI = protease inhibitor; PO = orally

TB among people with advanced immunodeficiency can be a rapidly progressive and fatal illness if treatment is delayed. Therefore, after collection of available specimens for culture and molecular diagnostic tests, empiric treatment for TB is recommended in patients with clinical and radiographic findings suggestive of HIV-related TB (AIII).

Treatment of TB for people with HIV is the same as for individuals without HIV151 although the current standard of care continues to evolve as new data emerge from clinical trials. Recommended dosing of drugs for treating active TB disease is summarized in the following table.

Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB
TB DrugARV DrugsDaily Dose
IsoniazidAll ARVs5 mg/kg (usual dose 300 mg)
Use INH with pyridoxine 25–50 mg PO daily
Rifampina,b
  • NRTIs (use TAF with cautionc)
  • EFV 600 mg
  • DTG, RAL (twice daily), MVC without a strong CYP3A4 inhibitor (note: doses of these ARVs need to be adjusted when used with rifampin)
  • IBA, T-20
10 mg/kg (usual dose 600 mg)
  • DOR, ETR, EFV 400 mg, NVP, RPV (PO)
  • BIC, EVG/c, RAL (daily)
  • CAB/RPV (IM/PO)
  • HIV PIs
  • LEN (SC/PO), FTR, MVC with a strong CYP3A4 inhibitor
Not recommended
Rifabutina
  • NRTIs (use TAF with cautionc)
  • ETR without boosted PIs
  • DOR and RPV (PO) (note: doses need to be adjusted when used with rifabutin)
  • DTG, RAL
  • MVC without a strong CYP3A4 inhibitor
  • IBA, T-20, FTR
5 mg/kg (usual dose 300 mg)
  • PIs with RTV MVC with a strong CYP3A4 inhibitor
150 mg dailye
  • EFV
450–600 mg
  • ETR with boosted PIs
  • BIC, EVG/c
  • CAB/RPV (IM/PO)
  • PIs with COBI
  • LEN (SC/PO)
Not recommended
Rifapentine
  • EFV
  • NRTIs (use TAF with cautionc)
1,200 mg/day for people weighing ≥40 kg
  • All other ARVs
Not recommended
PyrazinamideAll ARVs

Weight-based dosing

  • 40–55 kg: 1,000 mg
  • 56–75 kg: 1,500 mg
  • 76–90 kg: 2,000 mg
  • >90 kg: 2,000 mgf
EthambutolAll ARVs

Weight-based dosing

  • 40–55 kg: 800 mg
  • 56–75 kg: 1,200 mg
  • 76–90 kg: 1,600 mg
  • >90 kg: 1,600 mgf
Moxifloxacin
  • All ARVs
  • 400 mg daily for those weighing ≥40 kg

a For more detailed guidelines on use of different ARV drugs with rifamycin, clinicians should refer to the Drug–Drug Interactions section of the Adult and Adolescent Antiretroviral Guidelines.

b Higher doses may be needed in the treatment of TB meningitis. Expert consultation is advised.

c If TAF and rifamycins are coadministered, monitor for HIV treatment efficacy. Note that FDA labeling recommends not to coadminister. See text below and Table 4 for more information.

e Acquired rifamycin resistance has been reported in patients with inadequate rifabutin levels while on 150 mg three times per week dosing together with RTV-boosted PIs. May consider therapeutic drug monitoring (TDM) when rifabutin is used with an RTV-boosted PI and adjust dose accordingly.

f Monitor for therapeutic response and consider TDM to assure dosage adequacy in patients weighing >90 kg.

Note: For drug-drug interaction information between antiretrovirals and anti-TB drugs for treatment of drug-resistant TB, see the Adult and Adolescent Antiretroviral Guidelines. 

Key: ARV = antiretroviral; BIC = bictegravir; BID = twice a day; CAB = cabotegravir; COBI = cobicistat; DOR = doravirine; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG/c = elvitegravir/cobicistat; FTR = fostemsavir; IBA = ibalizumab; IM = intramuscular; INH = isoniazid; LEN = lenacapavir; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = oral; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SC = subcutaneous; T-20 = enfuvirtide; TAF = tenofovir alafenamide; TB = tuberculosis; TDM = Therapeutic Drug Monitoring

The preferred regimen for drug-susceptible TB includes a 2-month (8-week) intensive phase of isoniazid, rifampin, ethambutol, and pyrazinamide (AI). Ethambutol can be discontinued when susceptibility to isoniazid and rifampin has been confirmed. Thereafter, isoniazid and a rifamycin are used in the continuation phase of therapy, generally recommended as an additional 4 months (18 weeks) of treatment for uncomplicated TB (AI).151 Extension of therapy to 9 months is recommended for patients who have a positive sputum culture after 2 months of treatment or severe cavitary or disseminated extrapulmonary disease (BII).

A recently completed large, randomized clinical trial that enrolled 2,516 participants at 34 clinical sites in 13 countries established that a 4-month regimen of 2 months (8 weeks) of rifapentine, moxifloxacin, isoniazid, and pyrazinamide followed by 2 months (9 weeks) of rifapentine, moxifloxacin, and isoniazid was as effective as the standard 6-month regimen of isoniazid, rifampin, ethambutol, and pyrazinamide for two months followed by isoniazid and rifampin for an additional four months.152 In this study, the four-month regimen was non-inferior to the control regimen in both the microbiologically eligible and the assessable populations, with unfavorable outcome rates of 15.5% vs. 14.6% (95% CI, -2.6 to 4.5) and 11.6% vs. 9.6% (95% CI, -1.1 to 5.1) respectively. Additionally, the four-month regimen had slightly lower rates of grade 3 or higher adverse events than the control arm. While participants with HIV were included in the trial, the only antiretroviral therapy regimen allowed during the study was efavirenz-containing.153 This four-month regimen is now recommended as an alternative option for people with and without HIV who are 12 years of age or older (AI). It is not recommended for children under 12 years of age, pregnant people, people with extrapulmonary TB, or people with HIV who are taking a non-efavirenz-based antiretroviral regimen (AI).154 The trial also evaluated a four-month regimen with the same high dose of rifapentine but without moxifloxacin, which was found to be inferior to the control arm.

If rapid DST results indicate resistance to rifampin, with or without resistance to other drugs, an initial MDR TB regimen, as indicated below, should be used (BIII) and adjusted as molecular sequencing and conventional DST results become available.

Directly Observed Therapy (DOT)

DOT monitored by trained health care workers, who can be community-based or clinic-based, is recommended for all people with HIV-related TB (AII). Digital technology—such as video-DOT and pill sensors—may be useful alternatives to clinic-based or health care worker–based DOT.155-160 The likelihood of treatment success is further enhanced with comprehensive case management; assistance with housing and other social support; and, if needed, assistance to help people establish or re-engage with HIV care.151

Dosing and Duration of Therapy

Although intermittent dosing (administration less often than daily) facilitates DOT, regimens that included twice- or thrice-weekly dosing during the intensive or continuation phase have been associated with an increased risk of treatment failure or relapse with acquired drug resistance to the rifamycin class, particularly in people with HIV.161-169 Intermittent rifamycin use can result in the development of resistance in patients with HIV and is not recommended (AI). Therefore, daily therapy is recommended during both the intensive and continuation treatment phases (AII).151,167,168,170

Earlier recommendations171 for TB treatment in people without HIV indicated that therapy should be based on the number of doses received rather than the duration of therapy. However, no data substantiate the minimum number of doses needed within a specified time interval in people with HIV.151 Every effort should be made to ensure that people with HIV receive daily therapy as previously described.

The optimal duration of TB treatment for people with HIV and drug-susceptible TB disease has not been fully established. In general, the outcomes of 6-month regimens given as DOT to people with HIV have been favorable.2,151 A 1998 randomized but underpowered trial in the United States showed excellent and comparable outcomes of TB therapy among people with HIV assigned to 6 months or 9 months of therapy.172

Two trials in high-burden settings showed a higher risk of recurrent TB among people treated with 6 months of therapy than among those assigned to 9-month161 or 12-month regimens.173 However, the applicability of these two trials to low-burden settings—such as the United States—and in the context of universal ART is uncertain. In people with HIV receiving an efavirenz-based ART regimen, the 4-month alternative regimen of rifapentine, moxifloxacin, isoniazid, and pyrazinamide previously described was not associated with a higher rate of recurrent TB compared to the standard of care arm after follow-up out to at least 18 months post-TB treatment initiation.152,154 Whether outcomes with this 4-month regimen will be similar to standard 6-month anti-TB therapy in people with HIV treated with non-efavirenz-based ART is not known. Additional TB treatment shortening trials using alternative strategies in participants with HIV and TB coinfection are ongoing.

Treatment of TB Meningitis

With regard to the treatment of tuberculous meningitis, data regarding optimal drugs and doses to use are sparse. Many experts suggest that TB meningitis should be treated for an extended period of 9 to 12 months, but there is no evidence to support this recommended treatment duration.174 Recent clinical trials have suggested that the use of higher rifampin doses (up to 30–35 mg/kg/day) or the addition of fluoroquinolones or linezolid to initial treatment for TB meningitis may be beneficial, but the data are limited, particularly in people with HIV, and are insufficient to support a clear recommendation at this time.175-183 Adjunctive corticosteroid therapy is recommended for all individuals who have TB involving the CNS (AII) including those with HIV, as indicated below.

Adjunctive Corticosteroid Use in TB Treatment

Several clinical trials have demonstrated that adjunctive corticosteroid therapy increases survival overall for people with TB meningitis, improves treatment effectiveness, and reduces adverse event rates. These trials, however, either excluded people with HIV or were underpowered for detecting statistically significant outcome benefits in that group.111,184,185 A recent clinical trial compared adjunctive corticosteroids to placebo in people with HIV—the majority of whom had advanced HIV (52% of participants had a CD4 ≤50 cells/mm3)—and failed to find a statistically significant benefit (HR for death 0.85 [95% CI, 0.66–1.10]).186 The trial was powered to detect a 31% improvement in survival and it is possible that corticosteroids have a more modest effect. Importantly, the study found no evidence of harm with corticosteroids and, given the high morbidity and mortality associated with TB meningitis, adjunctive corticosteroids are still recommended in people with HIV and TB meningitis. Dexamethasone should be administered in a dose of 0.3 mg/kg/day to 0.4 mg/kg/day for 2 to 4 weeks, then tapered by 0.1 mg/kg per week until a dose of 0.1 mg/kg is reached, then 4 mg per day and tapered by 1 mg/week) for a total duration of 12 weeks (BII).111,151  

TB involving the CNS is currently the only organ system manifestation for which corticosteroids are recommended.151 Adjunctive corticosteroid therapy is not recommended in the treatment of TB pericarditis (AI). In a randomized trial that compared adjunctive prednisolone with placebo—each administered for 6 weeks in individuals with tuberculous pericarditis, with and without HIV—prednisolone was not associated with a significant reduction in the composite endpoint of death, cardiac tamponade, or constrictive pericarditis. Those receiving prednisolone also had a higher incidence of some cancers.187 A Cochrane review similarly found no mortality benefit from adjunctive corticosteroids and a nonsignificant reduction in constrictive pericarditis. Notably, however, <20% of people with HIV in the trials analyzed were receiving ART.188 No trials have been conducted comparing different doses and treatment durations of adjunctive corticosteroids.

Special Considerations Regarding ART Initiation

The preponderance of data from several large randomized trials in people with HIV and TB, as well as subsequent systematic reviews and meta-analyses, supports the recommendation that ART should not be withheld until completion of TB treatment (AI).108,189-196 ART is recommended for all people with HIV and TB (AI). For ART-naive patients, ART should be started within 2 weeks after TB treatment initiation in those with CD4 count <50 cells/mm3 when TB meningitis is not suspected (AI). For ART-naive patients with higher CD4 cell counts, ART should be started within 2-8 weeks of starting anti-TB treatment when TB meningitis is not suspected (AI). For ART-naïve patients with TB meningitis, ART should be started once the TB meningitis is under control—with either clinical improvement or improvement in CSF parameters—after at least 2 weeks of anti-TB treatment, to reduce the risk of immune reconstitution causing life-threatening inflammation in a closed space (AIII). Rifamycin-associated drug interactions should be considered when selecting the ARV drug regimen. Preemptive prednisone therapy should be offered to patients starting ART within 30 days after TB treatment initiation, have a CD4 count ≤100/mm3, are responding well to TB therapy and who do not have rifampin resistance, Kaposi sarcoma, or active hepatitis B (BI) (see TB-Associated IRIS below for details).197

American Thoracic Society (ATS)/CDC/Infectious Diseases Society of America (IDSA) guidelines recommend that people with TB meningitis should not start ART before 8 weeks of TB treatment is completed, regardless of CD4 count, based primarily on a randomized trial in 253 people with HIV and TB meningitis conducted in Vietnam. This trial compared immediate ART within 7 days of starting TB treatment with delayed ART started two months after starting TB treatment.151,193 The study showed no difference in mortality or TB outcomes, but those receiving immediate ART had a higher rate of severe adverse events. It is unclear whether the study’s findings are generalizable to higher-resourced settings with access to frequent monitoring and adjustment of dosing. We recommend that for ART-naive people with HIV and TB meningitis, ART should be started once the TB meningitis is under control, after at least 2 weeks of anti-TB treatment (AIII). The greatest risk of early ART is the occurrence of intracerebral TB-IRIS after starting ART, which has been reported in up to 50% of people with HIV and TB meningitis and may increase morbidity and mortality198 (although mortality was similar in both early and delayed ART arms in the only randomized trial completed to date).193 However, adjunctive corticosteroid therapy is recommended for all people with HIV and TB meningitis (AII) and precludes the need for pre-emptive use of prednisone to prevent IRIS. Whether the corticosteroid regimen recommended as adjunctive therapy for TB meningitis also further reduces the risk of TB IRIS and its consequences has not been evaluated.

In summary, early ART initiation requires close collaboration between HIV and TB care clinics, expertise in the management of ARV regimen selection, close monitoring, potential adjunctive corticosteroid therapy, and support and adherence services. The prevention and management of IRIS are discussed in detail below (see TB-Associated IRIS, below).

When TB occurs in people already on ART, treatment for TB must be started immediately (AIII), and ART should be modified to reduce the risk of drug interactions and to maintain virologic suppression. When TB occurs in the setting of virologic failure, ART drug-resistance testing should be performed, and intensified adherence counseling should be provided. A new ARV regimen may be required to achieve virologic suppression and minimize drug interactions with the anti-TB regimen.

Drug–Drug Interactions in the Treatment of HIV-Related TB

Dolutegravir in combination with two nucleoside(tide) reverse transcriptase inhibitors, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), abacavir, emtricitabine, or lamivudine, is the preferred regimen for co-treatment of HIV in most ART-naive people with TB (AI). This regimen can be managed with rifamycin-based anti-TB treatment (see Integrase Inhibitor section below for recommendations about dolutegravir dose adjustment if coadministered with rifampin). The following text summarizes the most important drug-drug interactions for antiretroviral drugs and anti-TB drugs to guide choices if other ART regimens are considered.

The rifamycin class of antibiotics is the cornerstone of effective and shorter-course first-line treatments for drug-sensitive TB. The currently available rifamycins (rifampin, rifabutin, and rifapentine) have clinically significant interactions with several ARV drugs. Most of these result from the rifamycin’s potent induction of genes involved in the metabolism and transport of ARV agents, and these interactions should be taken into consideration before initiating therapy (see Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB above, and the Tuberculosis/HIV Coinfection section of the Adult and Adolescent Antiretroviral Guidelines). Every effort should be made to include a rifamycin in the TB treatment regimen. Rifamycins remain the most potent drug class for TB treatment. Older regimens that included only 2 months of rifampin were associated with increased risks of treatment failure and TB recurrence among people with HIV-related TB.199,200 If a rifamycin cannot be used, TB treatment duration must be extended, and treatment complexity increases substantially. Thus, individuals with rifamycin-susceptible M. tuberculosis isolates should be treated with a regimen that includes a rifamycin unless a serious adverse event is highly likely due to a rifamycin (AIII).

No clinical trial has specifically compared rifampin- and rifabutin-containing anti-TB regimens among people with HIV and TB taking ART. Rifabutin is generally regarded as a reasonable substitute for rifampin for the treatment of active TB disease in people with HIV who concurrently receive ARVs that have adverse drug interactions with rifamycins, because rifabutin is a less potent inducer of CYP3A4 than rifampin.201 Although clinical trial data among people with HIV are limited to one small study, observational data among people with HIV, and several trials among people without HIV have found similar outcomes between those treated with rifampin or rifabutin.202-205

Nucleoside Reverse Transcriptase Inhibitor Backbone

Nucleoside(tide) backbone drugs—including tenofovir disoproxil fumarate (TDF), abacavir, emtricitabine, and lamivudine—can be given together with rifampin-containing TB treatment without dose adjustment. Tenofovir alafenamide (TAF), a substrate of drug transporters including P-glycoprotein, may be more likely to have drug–drug interactions than TDF. A study conducted among healthy volunteers without HIV showed that concentrations of intracellular tenofovir-diphosphate (TFV-DP) were higher with TAF/emtricitabine given with rifampin than with TDF given alone, suggesting that TAF may be given together with rifampin-containing TB treatment without dose adjustment.206 Neither TDF nor TAF has been fully evaluated with rifabutin. In one small study, though, HIV virologic suppression was sustained during TAF-rifabutin co-administration.207 In one study of TAF (as part of Biktarvy™) taken with daily high-dose rifapentine and isoniazid (1HP) for the treatment of LTBI, plasma tenofovir concentration was similar when TAF was taken alone versus together with 1HP, suggesting that TAF can be taken with rifapentine for short periods of time for prevention of TB.208

Non-Nucleoside Reverse Transcriptase Inhibitors—Efavirenz, Nevirapine, Etravirine, Doravirine, and Rilpivirine

One alternative co-treatment regimen for HIV-related TB disease is rifampin-based TB therapy with an ARV regimen of efavirenz (600 mg daily) plus two nucleoside(tide) analogues (AII). Studies in people with HIV and TB (including patients with higher body weight) have not shown a significant effect of rifampin-containing TB treatment on efavirenz plasma concentrations when used at the standard 600 mg per day dose in the majority of patients.209-211 Given the preponderance of data and the excellent treatment outcomes of co-treatment with standard-dose efavirenz,212,213 the 600 mg daily dose of efavirenz is recommended (AII). A small study among people with HIV found similar efavirenz concentrations when the 400 mg dose was taken with isoniazid and rifampicin versus when it was taken alone,214 suggesting that, while not recommended, rifampicin-based TB treatment could be given with efavirenz without a need for efavirenz dose adjustment. Pharmacokinetic studies also support the use of the 600mg efavirenz dose with the new 4-month rifapentine-moxifloxacin-isoniazid-pyrazinamide regimen.215

Nevirapine is not recommended for HIV and TB co-treatment (AII).216 The use of rifampin or rifapentine with doravirine, etravirine, or rilpivirine is not recommended (AIII) (see Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB, above, and the Tuberculosis/HIV Coinfection section of the Adult and Adolescent Antiretroviral Guidelines).

Some experts might consider substitution of rifabutin for rifampin with an appropriate dose adjustment of rifabutin (e.g., increasing to 450–600 mg daily when given with efavirenz) or of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) (e.g., increasing doravirine dosing to 100 mg twice daily and increasing oral rilpivirine to 50 mg daily), where appropriate,217,218 for patients who require one of these NNRTIs;219 however, IM rilpivirine, as used in long-acting ARV combinations, is not recommended (AIII). Rifabutin has not been evaluated in combination with rilpivirine, doravirine, or etravirine in people with HIV requiring treatment for active TB disease.

Integrase Inhibitors—Bictegravir, Dolutegravir, Elvitegravir, Raltegravir, and Cabotegravir

As indicated above, dolutegravir in combination with nucleoside reverse transcriptase inhibitors is the preferred option for co-treatment of HIV in most patients with TB (AI). A PK study in healthy volunteers showed that increasing the dose of dolutegravir to 50 mg twice a day with rifampin resulted in similar exposure to dolutegravir dosed 50 mg daily without rifampin, and that rifabutin 300 mg daily did not significantly reduce the area under the concentration curve of dolutegravir.220 A Phase 2 trial in people with HIV and TB (INSPIRING) demonstrated that PK targets and virologic suppression were favorable at 24 and 48 weeks when dolutegravir 50 mg twice daily was administered with rifampin-containing TB treatment.221 Dolutegravir is currently recommended at a dose of 50 mg twice daily when used together with a rifampin-containing TB regimen (AI) (and for two weeks following the completion of TB therapy), though randomized trials evaluating standard once-daily dosing are underway.222 Dolutegravir should be used at a standard 50 mg once-daily dose when used with rifabutin (AII).  

Another alternative co-treatment regimen is the combination of raltegravir-based ART, using raltegravir 800 mg twice daily, with standard rifampin dosing (BI).223 Raltegravir concentrations are decreased significantly when co-administered with rifampin. Increasing the dose of raltegravir to 800 mg twice daily mitigates this PK interaction.224 No PK or clinical data exist regarding the use of rifampin with the once-daily, extended-release 600 mg formulation of raltegravir, and co-administration is not recommended (AIII). Alternatively, raltegravir can be given with a rifabutin-containing TB regimen without a dose adjustment of either drug (BII).225

At this time, bictegravir should not be used together with rifamycin-containing TB treatment (rifampin, rifabutin, or rifapentine) (AII). A trial conducted among healthy participants without HIV evaluated bictegravir concentrations when given twice daily together with rifampin versus once daily alone.226 Bictegravir trough concentrations, with the dose adjustment, were reduced by 80%. Although studied only with rifabutin, elvitegravir/cobicistat is not recommended with TB treatment that contains rifamycins (AII).227,228 When given at steady-state with oral cabotegravir, rifampin decreased cabotegravir AUC by 59% in healthy volunteers.229 The long-acting injectable formulation of cabotegravir has not been studied with rifamycins, but a pharmacokinetic model of long-acting, injectable, co-formulated cabotegravir-rilpivirine predicted that concurrent rifampin would decrease cabotegravir AUC by 41% to 46%.230 As a result, oral and long-acting injectable cabotegravir is not recommended for use with rifampin or rifapentine (AII).229 Oral and long-acting injectable cabotegravir may be coadministered with rifabutin (AIII); however, long-acting injectable cabotegravir plus rilpivirine is not recommended for use with rifabutin due to the rilpivirine component (AIII).

Protease Inhibitors with Rifampin or Rifabutin

Rifampin decreases the plasma concentrations and exposure of co-administered PIs by >75%.231-234 One trial tested adjusted doses of ritonavir-boosted darunavir (1600/200 mg once daily and 800/100 mg twice daily) with rifampicin in people with HIV without TB.235 The trial was stopped early because of high rates of hepatotoxicity, and trough concentrations in the once-daily group were reduced substantially. Thus, boosted darunavir is not recommended for use together with rifampin, even with dose adjustment (AI).

The effects of rifampin on lopinavir/ritonavir PK may be overcome by doubling the dose of lopinavir/ritonavir.233,236 In a study of 71 people with HIV and TB, double doses of lopinavir/ritonavir were reasonably well tolerated in those on rifampin-based TB treatment.205 Some experts would consider this an alternative when a PI-based ART regimen is required during TB treatment (BI). Regular monitoring of transaminases and HIV RNA is recommended when double-dose lopinavir/ritonavir is used (e.g., more frequently initially, then monthly once transaminase levels are stable on full dose). Use of rifabutin with a boosted PI is preferred to the use of rifampin with double-dose PI in settings where rifabutin is readily available. Co-administered rifabutin has little effect on ritonavir-boosted lopinavir205,237 or atazanavir238 and only moderately increases concentrations of ritonavir-boosted darunavir239 and fosamprenavir.240 However, all PIs markedly increase serum concentrations of rifabutin (and one of its principal active metabolites, 25-O-desacetyl-rifabutin). Therefore, the dose of rifabutin must be decreased from 300 mg to 150 mg daily with all ritonavir-boosted PIs to avoid dose-related toxicity, such as uveitis and neutropenia (AI).205,241 Coadministration of cobicistat-boosted PIs with rifabutin is not recommended (AII).

In studies in people with HIV, rifabutin exposures were significantly lower when rifabutin was dosed at 150 mg three times weekly (with lopinavir/ritonavir) than when dosed at 300 mg daily without a PI, but concentrations of the active desacetyl metabolite were high.242,243 Among people with HIV and TB, cases have been reported of acquired rifamycin resistance when doses of rifabutin of 150 mg three times weekly were co-administered with a boosted PI-based ARV regimen.244,245 Based on available PK data, it is generally recommended that rifabutin be dosed 150 mg daily in patients who are on a ritonavir-boosted PI-containing ARV regimen (AI). However, given the potential risk of adverse events related to high levels of rifabutin’s metabolite with this dosing strategy, close monitoring for toxicity (especially neutropenia and uveitis) is required.205 Close monitoring of adherence to ART is essential because these reduced doses of rifabutin would be inadequate if the patient stopped taking the PI, putting the patient at risk of rifamycin-resistant TB.

Monitoring the Response to Therapy

Patients with pulmonary TB should have at least monthly sputum smears and cultures performed to document culture conversion on therapy (defined as two consecutive negative cultures) (AII). Sputum cultures from patients with susceptible TB typically convert to negative within 2 months of first-line TB therapy, although sputum culture conversion to negative may take longer for people with cavitary TB disease.246-248 Sputum cultures that do not convert to negative at or after 4 months of therapy indicate treatment failure and should prompt further evaluation, including drug-resistance testing of available specimens.

In patients with extrapulmonary TB, obtaining follow-up specimens can be challenging, making it difficult to assess a bacteriologic response to therapy. Instead, the response typically is measured by an improvement in clinical and radiographic findings, but the frequency of such evaluations will depend on the infected sites, the severity of disease, and the ease with which specimens can be obtained.

Managing Suspected Treatment Failure

The causes of treatment failure include undetected primary drug resistance, inadequate adherence to therapy, incorrect or inadequate prescribed regimen, subtherapeutic drug levels due to malabsorption or drug interactions, reinfection or mixed infection with drug-resistant M. tuberculosis, and acquired drug resistance.

People with suspected treatment failure should be evaluated with a medical history, physical exam, and chest radiograph to determine whether a clinical response to therapy has occurred despite the absence of sputum culture conversion. The initial culture results and drug-resistance tests, treatment regimen, and adherence to the regimen also should be reviewed. Some experts would perform therapeutic drug monitoring to determine if serum concentrations of the TB drugs are within expected ranges and adjust dosage as necessary.151,249 In addition, samples from all available sites (e.g., sputum, blood, urine) should be collected for repeat culture and DST, and strong consideration should be given to performing rapid resistance testing on direct specimens or positive cultures to identify acquired drug resistance or mixed infection with a drug-resistant strain.

While awaiting results of repeat cultures and rapid resistance testing, broadening empiric TB treatment to include at least two additional second-line TB drugs should be considered in consultation with an expert in the field (BIII).

Adverse Drug Reactions in TB Patients on Antiretroviral Therapy

Retrospective observational studies reported an increased risk of adverse drug reactions in patients treated with concomitant ART and anti-TB therapy. Many of these studies, however, included patients receiving older antiretrovirals which carried more frequent side effects.250 Three later randomized controlled trials reported similar rates of adverse events during anti-TB therapy with and without concomitant ART, suggesting no significant additive toxicity when ART is co-administered with anti-TB therapy.153,189,191 Nevertheless, managing suspected adverse drug reactions in this setting is complex because assigning causality to individual drugs in patients on anti-TB drugs, ART, and other agents is very difficult.

Because first-line anti-TB drugs are more effective and have fewer toxicities than alternative drugs, first-line drugs (especially isoniazid and rifampin or rifabutin) should not be stopped permanently, unless strong evidence exists that a severe drug reaction was caused by a specific anti-TB drug (AIII). In such situations, decisions regarding rechallenge with first-line drugs and/or substitution of second-line drugs may be made in consultation with a specialist in treating TB disease in people with HIV.

Liver transaminases should be monitored at baseline and monthly for those with underlying risk factors for hepatotoxicity.151 Drug-induced liver injury (DILI) can be caused by isoniazid, rifamycins, pyrazinamide, some ARV drugs, and trimethoprim-sulfamethoxazole (TMP-SMX). Anti-TB DILI is defined as an ALT elevation ≥3 times the upper limit of normal (ULN) in the presence of symptoms (e.g., fever, rash, fatigue, nausea, anorexia, jaundice); ALT ≥3 times the ULN plus total bilirubin 2 times the ULN in the absence of symptoms; or ALT ≥5 times the ULN alone in the absence of symptoms. An increase in ALT concentration occurs in approximately 5% to 30% of people treated with the standard four-drug anti-TB regimen,97,251 but many of these have only transient, mild elevations of ALT.97

If the criteria for anti-TB DILI are fulfilled, all potentially hepatotoxic drugs should be stopped, and the patient should be evaluated immediately (AIII). Serologic testing for syphilis and hepatitis A, B, and C should be performed, and the patient should be questioned regarding symptoms suggestive of biliary tract disease and exposures to alcohol and other hepatotoxins. At least three anti-TB drugs not associated with hepatoxicity should be started (e.g., ethambutol, linezolid, and moxifloxacin or levofloxacin)252 as a “bridging regimen” until the specific cause of hepatotoxicity can be determined and an alternative longer-term regimen constructed (BIII).

After the ALT level returns to <2.5 times the ULN (or to near baseline for those with preexisting abnormalities), rechallenge with the hepatotoxic first-line anti-TB medications can be started by adding each drug individually to the bridging regimen at 7-day intervals. During the rechallenge, ALT levels should be monitored frequently.

Rechallenge was successful in almost 90% of people without HIV in one randomized controlled trial of different rechallenge regimens.252 Because the rifamycins are a critical part of the TB regimen, they should be restarted first. Rechallenge with pyrazinamide is controversial because some studies have reported high rates of recurrent ALT elevations with reintroduction of the drug. Other studies, however, have demonstrated successful reintroduction of pyrazinamide,253,254 and some experts would therefore recommend rechallenge with pyrazinamide in people with severe forms of TB (e.g., meningitis or disseminated TB).

Bridging drugs can be stopped once three active nonbridging drugs are reinstated successfully. Depending on the outcome of the rechallenge, the anti-TB therapy regimen and duration may need to be altered, in which case, expert consultation is advised. After successful anti-TB drug rechallenge (i.e., if appropriate), relevant ARV drugs and TMP-SMX may be restarted.

Cutaneous adverse drug reactions may occur with all anti-TB drugs, notably rifampin and isoniazid255; some ARV drugs, notably the NNRTIs; and TMP-SMX. If the rash is minor, affects a limited area, and causes pruritus, antihistamines should be administered for symptomatic relief and all anti-TB medications should be continued. If the rash is generalized or associated with fever or DILI or involves mucous membrane or desquamation, all anti-TB medications, relevant ARVs, and TMP-SMX should be stopped. When the rash improves substantially, the TB drugs should be restarted as described in the section on DILI above. If the rash recurs, the last drug that had been added should be stopped and the TB regimen modified. Thereafter, if appropriate, relevant ARV drugs and TMP-SMX may be restarted.

Managing Drug-Resistant TB

Although drug-resistant TB represents a small fraction of the TB cases in the United States, the increasing number of people with drug-resistant TB globally plus the high proportion of TB cases in the United States in people who are from TB-endemic areas make it increasingly likely that local TB programs will be faced with this complex disease. The most active and effective TB drugs are those used in first-line TB treatment regimens. When resistance to these medications develops, alternative combinations of TB medications must be used, but clinical trial data on their optimal use are limited, and most recent studies have been conducted primarily in TB -endemic resource-constrained settings.

In the United States, approximately 7% of people with TB have baseline isoniazid mono-resistance.256 Growing evidence demonstrates an increased risk of treatment failure associated with isoniazid monoresistance,257 particularly in people with HIV and TB.258 For people with isoniazid monoresistance, it is recommended that a fluoroquinolone (levofloxacin or moxifloxacin) be substituted for isoniazid and given together with rifampin or rifabutin, pyrazinamide, and ethambutol for 6 months (BII).93,259-261 Though rifampin reduces concentrations of moxifloxacin by 20% to 40%, there is no clinical evidence that a moxifloxacin dose adjustment improves outcomes.262-264

The treatment of rifampin-resistant (RR) and MDR TB (resistance to both isoniazid and rifampin) is an area of active investigation and is evolving rapidly. Historically, RR/MDR TB has been treated with individualized regimens taking into account the results of drug resistance testing and prior treatment exposure. In 2019, ATS, CDC, IDSA, and the European Respiratory Society (ERS) issued MDR TB treatment guidelines recommending a fully oral regimen consisting of at least 5 active drugs for most patients with drug-resistant TB, including people with HIV.93

Since the publication of the 2019 guidelines, however, several clinical trials have examined the efficacy and safety of a 6-month, all-oral regimen comprised of bedaquiline, pretomanid, and linezolid (“BPaL"). Pretomanid is a novel oral antimycobacterial agent that was approved by the FDA in 2019 exclusively as part of the BPaL regimen. The initial study (“Nix-TB”) on which approval was based, was a single-arm study in 109 patients, of whom 51% were people with HIV.265 Although the study had no control arm, 90% of participants had a favorable outcome. High rates of peripheral neuropathy were seen in Nix-TB study participants, and this was attributed to the high dose of linezolid used (1200 mg daily). The follow-up ZeNix study (n=181) compared outcomes of patients receiving the BPaL regimen at different linezolid doses and showed similarly favorable outcomes with a lower dose of 600 mg daily.266 The TB-PRACTECAL study compared a regimen in which moxifloxacin was added to BPaL (aka “BPaLM”) to longer injectable-based regimens, which were the standard of care at the time.267,268 In modified intention-to-treat analyses, 121 of 138 (88%) participants in the BPaLM arm achieved treatment success compared with 81 of 137 (59%) of those receiving standard of care. Disease recurrence occurred in one participant in the BPaLM group (n=151) and four in the BPaL group (n=123); new resistance to bedaquiline was observed in the BPaL group in isolates from three of four recurrences, with no new resistance to other drugs in the regimens.267

The BPaL and BPaLM regimens have been used in the United States, and treatment outcomes thus far have been very successful among 152 patients with culture-positive pulmonary TB, most of whom received the 600 mg daily dose of linezolid.269,270 Three recurrences after treatment completion were reported among 116 who received BPaL and none among 36 patients who received BPaLM.

Based on these data, BPaLM is recommended as the preferred therapy for people with HIV with pulmonary RR-TB and without known resistance to the component medications (AI).271 Patients with RR-TB with fluoroquinolone resistance should receive BPaL without moxifloxacin (AI). This recommendation is similar to that of WHO, which conditionally recommends both the BPaL and BPaLM regimens to patients ≥15 years of age with RR-TB who have not had previous exposure or resistance to the drugs in the regimen.272 BPaLM and BPaL regimens should be given for a total of 26 weeks (6 months) (AI). Treatment should be extended up to a total of 39 weeks (9 months) if sputum cultures are positive between months 4 and 6 (AI).

For patients who have not been included in BPaL or BPaLM studies—such as those with extrapulmonary TB or those with known or suspected resistance to bedaquiline, pretomanid, or linezolid—we recommend an individualized regimen consisting of at least 5 active drugs, based on the results of resistance testing and prior treatment exposure (AI). Component medications should be selected using the ranking outlined in the ATS/CDC/IDSA/ERS guidelines.93 When possible, an initial individualized regimen should contain bedaquiline, linezolid, a fluoroquinolone (levofloxacin or moxifloxacin), clofazimine, and a D-alanine analog (cycloserine or terizidone). All remaining drugs should be used to complete the regimen only when the recommended drugs cannot be used. Kanamycin and capreomycin are no longer recommended due to the increased risk of treatment failure and relapse with their use.273 Such an association was not seen for amikacin, which may be used when other, less toxic drugs cannot be used. The duration of therapy with such a regimen will depend on the component drugs and the patient’s response to therapy. The ATS/CDC/IDSA/ERS guidelines currently recommend a treatment duration of 15 to 24 months after culture conversion when using an individualized regimen, although these guidelines are currently undergoing revision.93 Several clinical trials have examined different regimens with total durations as short as 9 months and show TB treatment success rates comparable to or better than longer duration therapy.274-278 Consultation with an expert who has experience managing drug-resistant TB is advised.

An important concern regarding BPaL(M) regimens is the growing prevalence of bedaquiline resistance and the lack of widespread availability of phenotypic second-line TB drug susceptibility testing.279,280 Rapid molecular testing with confirmatory sequencing for fluoroquinolones and first-line drugs should ideally be performed prior to the initiation of treatment for RR/MDR TB; phenotypic testing should also be undertaken. This testing, as well as susceptibility testing for second-line agents, is available at many local or state public health laboratories or through the CDC’s Molecular Detection of Drug Resistance (MDDR) service. To submit a sample for the MDDR service, complete the CDC’s MDDR Request Form.

Importantly, as with all TB drugs, there is incomplete concordance between purported bedaquiline resistance-conferring mutations and phenotypic resistance.281 If bedaquiline is being used, then bedaquiline phenotypic testing should be pursued, if available. Treatment with BPaLM need not be delayed, however, while awaiting the results of bedaquiline susceptibility testing. Of note, pretomanid resistance testing is not currently available.

For people with HIV with RR-TB, several important drug–drug interactions occur between bedaquiline and some ARV drugs. Specifically, efavirenz decreases bedaquiline plasma concentrations.282 For people with HIV with RR-TB, efavirenz should not be used concurrently with bedaquiline (AI). Lopinavir/ritonavir increases bedaquiline plasma concentrations approximately twofold when given at steady-state,283,284 but this has not been associated with additional prolongation of the QT-interval or other adverse events.285

Given the options for regimen choice and individual drug dosing within regimens, as well as variations in local drug susceptibilities, the treatment of RR-TB should involve an expert with experience in treating drug-resistant TB.267,269 If a local expert is not available through the public health department, clinicians and TB programs can contact the CDC (tbinfo@cdc.gov) and one of the CDC’s TB Centers of Excellence for Training, Education, and Medical Consultation.

TB-Associated IRIS

TB-IRIS is a frequent, early complication of ART in people with HIV with active TB. The condition is thought to result from the recovering immune system driving inflammatory reactions directed at M. tuberculosis antigen present at sites of disease.286-288 TB-IRIS is characterized by excessive local or systemic inflammation. Two forms of TB-IRIS are recognized: paradoxical TB-IRIS and unmasking TB-IRIS. Proposed clinical case definitions for these syndromes have been published.289

Paradoxical TB-IRIS

Paradoxical TB-IRIS occurs in people who are diagnosed with active TB disease before starting ART. Typically, people experiencing paradoxical TB-IRIS have had clinical improvement on TB treatment before starting ART, and within the first 1 to 4 weeks of ART (though sometimes later), they develop new or recurrent symptoms and worsening or recurrent clinical and radiologic features of TB. Common and important manifestations of paradoxical TB-IRIS include fevers, new or enlarging lymphadenopathy, and new or worsening pulmonary infiltrates. Mortality due to paradoxical TB-IRIS is uncommon,287,290 but life-threatening manifestations include enlarging cerebral tuberculomas, meningitis, enlargement of pericardial effusions causing cardiac tamponade, extensive pulmonary involvement with respiratory failure, nodal enlargement causing airway obstruction, and splenic rupture due to rapid enlargement.287,291,292 In people with disseminated TB, hepatic TB-IRIS is common, manifesting with nausea and vomiting, tender hepatic enlargement, cholestatic liver function derangement, and occasionally jaundice.288,293 A liver biopsy often reveals granulomatous hepatitis.294 Hepatic TB-IRIS may be difficult to differentiate from drug-induced liver injury.

Paradoxical TB-IRIS is relatively common among patients starting ART while on TB treatment. A meta-analysis of 40 studies reported a pooled incidence of TB-IRIS of 18% in adults with HIV-associated TB initiating ART, with death attributed to TB-IRIS in 2% of the cases.295 The onset of paradoxical TB-IRIS symptoms is typically between 1 to 4 weeks after ART is initiated.296-301 The syndrome lasts for 2 to 3 months on average,300,302 but in some cases, symptoms may continue for several more months, and in rare cases, local manifestations may persist or recur over a year after onset.289,302,303 In such cases of prolonged TB-IRIS, manifestations usually include suppurative lymphadenitis and abscess formation.

The most consistently identified risk factors for paradoxical TB-IRIS are a low CD4 count at the start of ART, especially a CD4 count239,244 <100 cells/mm3;299,304 high HIV viral load before ART305,306; disseminated or extrapulmonary TB291,298,300,304; and a short interval between starting TB treatment and initiating ART, particularly if ART is started within the first 1 to 2 months of TB treatment.291,297,299 Although early ART increases the risk for TB-IRIS, ART should be started within 2 weeks of TB diagnosis in patients with CD4 counts <50 cells/mm3 and within 2 to 8 weeks of TB diagnosis in those with higher CD4 counts, as previously discussed, to reduce the risk of HIV progression and death (see Special Considerations Regarding ART Initiation, above) (AI).295

The diagnosis of paradoxical TB-IRIS may be challenging, and no definitive confirmatory test exists. Thus, diagnosis relies upon a characteristic clinical presentation: improvement of TB symptoms with treatment before ART, deterioration with inflammatory features of TB soon after starting ART, or demonstration of a response to ART (CD4 rise and/or HIV viral load reduction). In addition, diagnosis of paradoxical TB-IRIS requires investigations to exclude alternative causes for deterioration, particularly another opportunistic infection, undetected TB drug resistance, or other cause of treatment failure (see Managing Suspected Treatment Failure, above).307

Prevention of Paradoxical TB-IRIS

Pre-emptive treatment with prednisone may prevent or reduce the consequences of TB-IRIS. A randomized, double-blind, placebo-controlled trial of prednisone (40 mg/day for 2 weeks, then 20 mg/day for 2 weeks) versus placebo in 240 ART-naive adults at high risk of developing IRIS at the time of ART initiation demonstrated that preemptive prednisone treatment was effective in reducing the risk of paradoxical TB-IRIS.197 The incidence of TB-IRIS was 47% in the placebo arm and 33% in the prednisone arm (RR = 0.70; 95% CI, 0.51–0.96). No excess risk was observed for malignancy, severe infections, or other complications. Based on these study findings, preemptive prednisone therapy should be offered for high-risk patients as defined in this study (i.e., starting ART within 30 days after TB treatment initiation and a CD4 count ≤100/mm3) who are responding well to TB therapy and who do not have rifampin resistance, Kaposi sarcoma, or active hepatitis B (BI).

Managing Paradoxical TB-IRIS

Most cases of paradoxical TB-IRIS are self-limiting. Many people require symptomatic therapy (e.g., analgesia, anti-emetics), and if symptoms are significant, anti-inflammatory therapy is appropriate. Clinicians may use non-steroidal anti-inflammatory drugs to provide symptomatic relief in patients with mild TB-IRIS (CIII). Needle aspiration of enlarging serous effusions, large tuberculous abscesses, or suppurative lymphadenitis may also provide symptom relief (CIII). Repeated aspirations may be required as abscesses and effusions often re-accumulate.291

In people with moderately severe paradoxical TB-IRIS, treatment with prednisone is recommended (AI). One randomized, placebo-controlled trial among patients with moderately severe paradoxical TB-IRIS showed that treatment with prednisone (1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks) resulted in a reduction in a combined endpoint of days hospitalized plus outpatient therapeutic procedures.308 In that study, however, 4 weeks of prednisone treatment was insufficient in a subset of participants. If clinical assessment indicates that signs and symptoms have not improved or have worsened as corticosteroids are tapered, a more gradual tapering of steroids over 2 to 3 months is recommended (BIII).308 Patients on prednisone experienced more rapid symptoms and radiographic improvement. No reduction in mortality was demonstrated, but immediately life-threatening cases (e.g., those with neurological involvement) were excluded from this study.111,292,308 Rifampin increases the clearance of prednisolone (the active metabolite of prednisone),309 but no such effect is expected with rifabutin; dosing of prednisone should therefore be adjusted in patients receiving rifampin or rifabutin-containing regimens (See the Treating TB-Associated IRIS section of the Treating TB Disease table). Corticosteroids should be avoided in people with Kaposi sarcoma because life-threatening exacerbations can occur. Case reports have been published of patients with steroid-refractory and prolonged IRIS or paradoxical reactions responding to TNF-blockers, IL-1 inhibitors, JAK inhibitors, or thalidomide.310-317

Unmasking TB-IRIS

Unmasking TB-IRIS may occur in people who have unrecognized TB (because TB is either symptomatic or it has eluded diagnosis) at the start of ART. These people may present with a particularly accelerated and inflammatory presentation of TB in the first weeks of ART.289 A common presentation is pulmonary TB with rapid symptom onset and clinical features similar to bacterial pneumonia with high fever, respiratory distress, sepsis syndrome, and consolidation on chest radiograph.289,308,318-320 Focal inflammatory manifestations—such as abscesses and lymphadenitis— also may develop.321 In cases of unmasking TB-IRIS, the treatment should be standard TB treatment and, if the manifestations are life-threatening, adjunctive corticosteroid therapy is recommended, although steroid use in this setting has not been studied in a clinical trial (BIII).

Prevention of Recurrent TB

Among patients receiving the same TB treatment regimen in the same setting, the risk of recurrent TB appears to be higher among those with HIV than among those without HIV.322,323 In TB-endemic settings, much of the increased risk of recurrent TB appears to be due to the higher risk of re-infection with a new strain of M. tuberculosis, with subsequent rapid progression to TB disease.324,325 In settings with low rates of TB—such as the United States—recurrent TB due to re-infection is uncommon, even among people with HIV.326

Several interventions may decrease the risk of recurrent TB among people with HIV: longer TB treatment regimens, administering therapy daily throughout the course of the intensive and continuation phases, post-treatment isoniazid therapy, and use of ART. None of these interventions has been adequately evaluated in randomized trials in settings with low TB burdens. Post-treatment isoniazid (6–9 months of daily isoniazid therapy after the completion of standard multidrug therapy) has been shown to be effective in high-burden settings in which the risk of re-exposure is high,327,328 suggesting that this intervention decreases the risk of re-infection. Post-treatment isoniazid is not recommended for patients in the United States or other low-burden settings due to a lack of evidence of effectiveness supporting a reduced risk of re-infection for these settings (AIII). Given that ART reduces the risk of initially developing TB disease, it is likely that ART also decreases the risk of re-infection with TB.

Special Considerations During Pregnancy

Pregnant people with HIV who do not have documentation of a prior negative TB screening test result or who are at high risk for repeated or ongoing exposure to individuals with active TB disease should be tested for TB during pregnancy (AIII). TB rates in pregnant and postpartum women are higher than in non-pregnant adults, after adjusting for age,329 and this is likely due to pregnancy-related immunologic shifts.330-334 Several studies have examined the performance of IGRAs for diagnosis of LTBI in pregnant women. In pregnant women with or without HIV, the test appears to perform well.335,336 Longitudinal studies conducted in high-burden countries, however, suggest that test performance may be compromised in late pregnancy versus postpartum, especially at delivery.337-343

A clinical trial of isoniazid preventive therapy (IPT) among HIV-infected women in high TB prevalence settings (TB APPRISE) found increased adverse pregnancy outcomes in women treated with isoniazid during pregnancy compared to postpartum initiation of isoniazid.344 Importantly, however, none of the women were close household TB contacts, and most of the women in the trial were IGRA-negative and were receiving efavirenz-based ART. Two smaller observational studies of isoniazid given to pregnant women with HIV in South Africa did not find an increased risk of adverse pregnancy outcomes with isoniazid.345,346 Similarly, a study of participants in Botswana who became pregnant in a trial of 36 months of isoniazid for people with HIV also did not report increased adverse pregnancy outcomes.347 A subsequent systematic review of the association of adverse pregnancy outcomes and isoniazid found inconsistent associations.348 Among people enrolled in the BRIEF-TB study who became pregnant while taking isoniazid for TB prevention, first-trimester IPT exposure was associated with increased risk of fetal demise, though this association was attenuated when adjusted for covariates proximal to pregnancy outcome including ART use. 349

Studies in individuals with HIV who are not receiving ART have shown a high risk of progression from LTBI to active TB disease (10% per year), and a high risk exists for maternal and infant mortality in pregnant women with HIV who have active TB disease.350,351 Although the risk of progression from LTBI to active TB disease in individuals on ART is decreased significantly, risk in these individuals with HIV appears higher than in pregnant and postpartum people without HIV.337,352 Pregnant people with HIV should be receiving ART both for their own health and for prevention of perinatal transmission (AI). In the United States, isoniazid preventive therapy is recommended for pregnant women with HIV whose close household contacts include a person with active TB disease (AI). For those receiving effective ART and without recent TST or IGRA conversion or close household contacts with infectious TB, therapy for LTBI may be deferred until after delivery (BIII). The risk of isoniazid-associated hepatotoxicity may be increased in pregnancy and in the first 2 to 3 months post-partum.344 Therefore, if isoniazid is prescribed, frequent monitoring is needed.34 Pregnant people receiving isoniazid should receive daily pyridoxine supplementation (AII) because they are at risk of isoniazid-associated peripheral neuropathy.151,353 Limited data exist on alternatives to isoniazid for LTBI therapy in pregnant people with HIV. In the IMPAACT 2001 study, pregnant women with and without HIV received 3HP and no serious adverse pregnancy outcomes were observed. Drug exposures were similar to non-pregnant adults, suggesting this regimen does not require dose adjustment in pregnancy.354 Despite these promising data and although rifampin generally is considered safe in pregnancy, data on the use of rifapentine remain extremely limited and the use of rifapentine in pregnant people is not currently recommended (BIII).355-357 The DOLPHIN Moms trial (NCT05122026) currently underway is examining the pharmacokinetics and safety of 3HP and 1HP in pregnant people with HIV who are virally suppressed on a dolutegravir-based regimen.

The diagnostic evaluation for TB disease in pregnant people is the same as for nonpregnant adults. It is important to recognize that standard symptom screens have lower sensitivity in pregnant women than in non-pregnant adults, and that some TB symptoms may be masked by common symptoms of pregnancy (e.g. poor appetite).358-360 In addition to standard sputum testing, chest radiographs with abdominal shielding are recommended and result in minimal fetal radiation exposure.361 An increase in pregnancy complications—including preterm birth, low birthweight, and fetal growth restriction—can be among pregnant women with either pulmonary or extrapulmonary TB not confined to the lymph nodes, especially when TB treatment is delayed until late in pregnancy.34,330,333,335,336,339,344,351,362-366 Congenital TB infection has been reported, although it appears relatively uncommon; history of maternal infertility and acid-fast bacilli from placenta or endometrial biopsy may be found with this rare diagnosis.367-372 While rare, congenital TB might be more common among children born to mothers with TB/HIV coinfection, especially when those children also have perinatally acquired HIV.373,374

TB therapy should not be withheld because of pregnancy (AIII). Treatment of TB disease should be the same for pregnant people and nonpregnant people, but with attention to the following considerations (AIII):

  • Although isoniazid is not teratogenic in animals or humans, hepatotoxicity caused by isoniazid might occur more frequently during pregnancy and the postpartum period.375 Monthly monitoring of liver transaminases during pregnancy and the postpartum period is recommended (BIII).
  • Rifampin is not teratogenic in humans.
  • Ethambutol is teratogenic in rodents and rabbits at doses that are much higher than those used in humans. No evidence of teratogenicity has been observed in humans. Ocular toxicity has been reported in adults taking ethambutol but changes in visual acuity have not been detected in infants exposed to ethambutol in utero.
  • Pyrazinamide is not teratogenic in animals. The WHO and the International Union Against Tuberculosis and Lung Diseases have made recommendations for the routine use of pyrazinamide in pregnant individuals.272,376 Pyrazinamide has been recommended for use in pregnant people in the United States, although data characterizing its safety in this setting are limited and the CDC guidance suggests that clinicians consider the use of this agent based on individual patient considerations weighing benefit and risks.151,377 If pyrazinamide is not included in the initial treatment regimen, the minimum duration of TB therapy with isoniazid, rifampin, and ethambutol should be 9 months for drug-susceptible TB (AII). The decision regarding whether to include pyrazinamide in treatment regimens for a pregnant person should be made after consultation among obstetricians, TB specialists, and the patient, while considering gestational age and likely susceptibility pattern of the TB strain.

Experience using the majority of the second-line drugs for TB during pregnancy is limited.378-381 MDR TB in pregnancy should be managed in consultation with a specialist. In a small prospective study of pregnant patients who received second-line MDR/RR-TB regimens that contained bedaquiline or delamanid (including linezolid, clofazimine, amikacin, capreomycin, and kanamycin) 98% had successful treatment outcomes, and at least 81% of continued pregnancies resulted in live births with 68% normal birthweight neonates.378 The following concerns should be considered when selecting second-line anti-TB drugs for use in pregnant people:

  • Bedaquiline: Data on the use of bedaquiline in pregnancy are limited, but a study of 108 pregnant women from South Africa found an increased frequency of low birthweight (<2,500 g) among children exposed to bedaquiline in utero compared to those who were not exposed (45% vs. 26%; P = 0.034).382 The median birthweight between the two groups, however, was not statistically significant (2690 vs. 2900 grams [P = 0.18]) and after 1 year, most children exposed to bedaquiline had gained weight and were doing well. Bedaquiline concentrations in breast milk may be as high or higher than concentrations in maternal plasma, which may have implications for the infant.383,384
  • Cycloserine: No data are available from animal studies or reports of cycloserine use in humans during pregnancy.
  • Ethionamide has been associated with an increased risk for several anomalies in rats after high-dose exposure, but not in mice or rabbits.385-387 Case reports have documented cases of CNS defects in humans and hypothyroidism, but overall experience is limited with use during human pregnancy.388 Ethionamide is likely present in the breast milk, which could be associated with thyroid issues in the infant. Thus, ethionamide should be avoided, unless its use is required on the basis of susceptibility testing (CIII).
  • Fluoroquinolones: Because arthropathy has been noted in immature animals exposed to fluoroquinolones in utero, quinolones are typically not recommended for pregnant people or children aged <18 years (CIII). However, studies evaluating fluoroquinolone use in pregnant women did not find an increased risk of birth defects or congenital musculoskeletal abnormalities.389-393 Furthermore, fluoroquinolones were used in a larger South African case series of MDR TB treatment in pregnancy with generally good outcomes.382 Thus, fluoroquinolones can be used in pregnancy for drug-resistant TB if they are required on the basis of susceptibility testing (BII).394
  • Linezolid: Animal studies of linezolid in pregnancy report decreased fetal body weight and increased fusion of costal cartilage.395 There are few studies in human pregnancy, but linezolid has been used for the treatment of DR-TB in some high-burden countries.378,382 In these case studies, monitoring complete blood counts for anemia and thrombocytopenia and advising iron supplementation has been recommended.384,396
  • Delamanid: Delamanid appears to be safe in animal reproductive toxicity studies. It has been used in small cohorts of pregnant women for DR-TB with favorable outcomes.378,397
  • Pretomanid: Animal studies of pretomanid do not indicate direct or indirect harmful effects with respect to embryo-fetal development. However, pretomanid has been associated with reproductive toxicity in animal models; specifically, reduced fertility in male rats.398 There has been very limited use in human pregnancies. Therefore, pretomanid should be avoided in pregnancy until more data is available (AIII).
  • Para-aminosalicylic acid is not teratogenic in rats or rabbits.377 In one study, a possible increase in limb and ear anomalies was reported among 143 infants delivered by women who were exposed to para-aminosalicylic acid during the first trimester of pregnancy.399 No specific pattern of defects and no increase in the rate of defects have been detected in other human studies, indicating that this agent can be used with caution, if needed (CIII).
  • Aminoglycosides/polypeptides: Streptomycin use has been associated with a 10% rate of vestibulocochlear nerve toxicity in infants exposed to the drug in utero; its use during pregnancy should be avoided, if possible (AIII). Hearing loss has been detected in approximately 2% of children exposed to long-term kanamycin therapy in utero; like streptomycin, this agent should typically be avoided, if possible (AIII). The fetus is at a theoretical risk for ototoxicity with in utero exposure to amikacin and capreomycin, but this risk has not been documented. Capreomycin is no longer recommended, but amikacin might be used as an alternative when an aminoglycoside is required for the treatment of MDR TB (CIII).

References

  1. World Health Organization. Global tuberculosis report 2021. 2021. Available at: https://www.who.int/publications/i/item/9789240037021.
  2. World Health Organization. Global tuberculosis report 2022. 2022. Available at: https://www.who.int/publications/i/item/9789240061729.
  3. Filardo TD, Feng PJ, Pratt RH, Price SF, Self JL. Tuberculosis - United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(12):441-446. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35324877.
  4. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30 Suppl 1:S5-14. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10770911.
  5. Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010. J Infect Dis. 2016;214(6):862-872. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27559122.
  6. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2021. 2021. Available at: https://www.cdc.gov/tb/statistics/reports/2021/table19.htm.
  7. Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4). Available at: https://www.ncbi.nlm.nih.gov/pubmed/30021818.
  8. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2(16076). Available at: https://www.nature.com/articles/nrdp201676.
  9. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320(9):545-550. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2915665.
  10. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268(4):504-509. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1619742.
  11. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med. 1993;119(3):194-198. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8100693.
  12. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA. 1995;274(2):143-148. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7596002.
  13. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med. 1997;126(2):123-132. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9005746.
  14. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131-138. Available at: https://www.ncbi.nlm.nih.gov/pubmed/4810628.
  15. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191(2):150-158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15609223.
  16. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23(1):75-80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10708059.
  17. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):111-115. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28052967.
  18. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010(1):CD000171. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20091503.
  19. Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32156698.
  20. Miramontes R, Hill AN, Yelk Woodruff RS, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One. 2015;10(11):e0140881. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26536035.
  21. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080-e1089. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29025631.
  22. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682-690. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24835842.
  23. Temprano ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26193126.
  24. Ross JM, Badje A, Rangaka MX, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV. 2021;8(1):e8-e15. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33387480.
  25. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21(11):1441-1448. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17589190.
  26. Holzman SB, Perry A, Saleeb P, et al. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. Clin Infect Dis. 2022;75(10):1792-1799. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35363249.
  27. Wilson IB, Landon BE, Hirschhorn LR, et al. Quality of HIV care provided by nurse practitioners, physician assistants, and physicians. Ann Intern Med. 2005;143(10):729-736. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16287794.
  28. Backus LI, Boothroyd DB, Phillips BR, et al. National quality forum performance measures for HIV/AIDS care: the Department of Veterans Affairs' experience. Arch Intern Med. 2010;170(14):1239-1246. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20660844.
  29. Lee LM, Lobato MN, Buskin SE, Morse A, Costa OS. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis. 2006;10(2):209-214. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16499263.
  30. Reaves EJ, Shah NS, France AM, et al. Latent tuberculous infection testing among HIV-infected persons in clinical care, United States, 2010-2012. Int J Tuberc Lung Dis. 2017;21(10):1118-1126. Available at: https://pubmed.ncbi.nlm.nih.gov/28911355/.
  31. Fisk TL, Hon HM, Lennox JL, Fordham von Reyn C, Horsburgh CR, Jr. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS. 2003;17(7):1102-1104. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12700468.
  32. Girardi E, Palmieri F, Zaccarelli M, et al. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. AIDS. 2002;16(14):1976-1979. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12351964.
  33. Overton K, Varma R, Post JJ. Comparison of interferon-gamma release assays and the tuberculin skin test for diagnosis of tuberculosis in human immunodeficiency virus: a systematic review. Tuberc Respir Dis (Seoul). 2018;81(1):59-72. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29256218.
  34. Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers. 2020. Available at: https://www.cdc.gov/tb/publications/ltbi/default.htm.
  35. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med. 1993;119(3):185-193. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8100692.
  36. Auguste P, Tsertsvadze A, Pink J, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):200. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28274215.
  37. Ho CS, Feng PI, Narita M, et al. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infect Dis. 2022;22(1):85-96. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34499863.
  38. Pettit AC, Stout JE, Belknap R, et al. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among US-born people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2021;73(7):e2278-e2284. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32761083.
  39. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230-238. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21239993.
  40. Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis. 2012;54(3):e20-23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22057704.
  41. Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(19):439-443. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31099768.
  42. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007;175(7):737-742. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17218620.
  43. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009;9:15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19208218.
  44. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45-55. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21846592.
  45. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One. 2008;3(1):e1379. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18167540.
  46. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-962. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19245343.
  47. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177(10):1164-1170. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18276940.
  48. Leung CC, Yam WC, Yew WW, et al. T-Spot.TB outperforms tuberculin skin test in predicting tuberculosis disease. Am J Respir Crit Care Med. 2010;182(6):834-840. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20508217.
  49. Ledesma JR, Ma J, Zheng P, Ross JM, Vos T, Kyu HH. Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis. BMC Infect Dis. 2021;21(1):467. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34022827.
  50. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1-25. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20577159.
  51. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21267059.
  52. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(9):e515-e523. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30139576.
  53. Stuck L, van Haaster AC, Kapata-Chanda P, Klinkenberg E, Kapata N, Cobelens F. How "subclinical" is subclinical tuberculosis? An analysis of National Prevalence Survey data from Zambia. Clin Infect Dis. 2022;75(5):842-848. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34984431.
  54. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32053584.
  55. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631-636. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19525621.
  56. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588-1598. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21492926.
  57. Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine plus isoniazid for treatment of Mycobacterium tuberculosis infection in HIV co-infected persons. AIDS. 2016;30(10):1607-1615. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26990624.
  58. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11-20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21732833.
  59. Belknap R, Holland D, Feng PJ, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689-697. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29114781.
  60. Podany AT, Bao Y, Swindells S, et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322-1327. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26082504.
  61. Farenc C, Doroumian S, Cantalloube C, et al. Rifapentine once-weekly dosing effect on efavirenz emtricitabine and tenofovir PKs. Presented at: Conference on Retroviruses and Opportunistic Infections; 2014. Boston, MA. Available at: https://www.croiconference.org/abstract/rifapentine-once-weekly-dosing-effect-efavirenz-emtricitabine-and-tenofovir-pks.
  62. Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079-1085. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24343893.
  63. Dooley KE, Savic R, Gupte A, et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7(6):e401-e409. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32240629.
  64. Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67(25):723-726. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29953429.
  65. U.S. National Library of Medicine. Safety tolerability DDI short course treatment of LTBI infection with high-dose rifapentine and isoniazid or standard isoniazid preventive therapy in HIV+ patients (DOLPHIN & DOLPHIN TOO) (IMPAACT4TB). 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT03435146.
  66. Hong Kong Chest Service/Tuberculosis Research Centre; Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1992;145(1):36-41. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1731596.
  67. Geijo MP, Herranz CR, Vano D, Garcia AJ, Garcia M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007;25(5):300-304. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17504682.
  68. Jimenez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiro J, Altet-Gomez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013;17(3):326-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23407221.
  69. Martinez Alfaro E, Solera J, Serna E, et al. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. Med Clin (Barc). 1998;111(11):401-404. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9834911.
  70. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670-676. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15714411.
  71. Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr. 2001;28(3):305-307. Available at: https://pubmed.ncbi.nlm.nih.gov/11694842/.
  72. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15(16):2137-2147. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11684933.
  73. Rivero A, Lopez-Cortes L, Castillo R, et al. [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin. 2007;25(5):305-310. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17504683.
  74. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337(12):801-808. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9295239.
  75. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1997;337(5):315-320. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9233868.
  76. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997;11(7):875-882. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9189212.
  77. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440-453. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30067931.
  78. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22150035.
  79. Horsburgh CR, Jr., Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401-409. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19793865.
  80. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847-850. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10524579.
  81. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555-564. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6754120.
  82. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283(11):1445-1450. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10732934.
  83. Swindells S, Ramchandani R, Gupta A, et al. One Month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11):1001-1011. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30865794.
  84. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689-697. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19017587.
  85. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292-297. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19656705.
  86. Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis. 2012;55(12):1698-1706. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22955441.
  87. den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065-1071. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27393541.
  88. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6(11):995-1000. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12475146.
  89. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest. 2003;123(1):102-106. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12527609.
  90. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations--United States, 2001. MMWR. 2001. Available at: https://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf.
  91. Podany AT, Leon-Cruz J, Hakim J, et al. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2021;76(3):718-721. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33241266.
  92. U.S. National Library of Medicine. Drug-drug interactions between rifapentine and dolutegravir in HIV/LTBI co-infected individuals. 2023. Available at: https://clinicaltrials.gov/study/NCT04272242.
  93. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10). Available at: https://www.atsjournals.org/doi/ref/10.1164/rccm.201909-1874ST.
  94. U.S. National Library of Medicine. Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients (PHOENIx MDR-TB). 2023. Available at: https://clinicaltrials.gov/study/NCT03568383?cond=NCT03568383&rank=1.
  95. Bliven-Sizemore EE, Sterling TR, Shang N, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19(9):1039-1044. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26260821.
  96. Ngongondo M, Miyahara S, Hughes MD, et al. Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial. J Acquir Immune Defic Syndr. 2018;78(1):54-61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29406428.
  97. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-952. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17021358.
  98. Kendall EA, Shrestha S, Dowdy DW. The epidemiological importance of subclinical tuberculosis. A critical reappraisal. Am J Respir Crit Care Med. 2021;203(2):168-174. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33197210.
  99. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362(8):707-716. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20181972.
  100. Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van de Perre P. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis. 1992;146(1):53-56. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1626814.
  101. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148(5):1292-1297. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7902049.
  102. Dhana A, Hamada Y, Kengne AP, et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. Lancet Infect Dis. 2022;22(4):507-518. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34800394.
  103. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1997;25(2):242-246. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9332519.
  104. Post F, Wood R, Pillay G. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuber Lung Dis. 1995;76:518-21. Available at https://pubmed.ncbi.nlm.nih.gov/8593372.
  105. Pepper T, Joseph P, Mwenya C, et al. Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis. 2008;12(4):397-403. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18371265.
  106. Ahuja SS, Ahuja SK, Phelps KR, Thelmo W, Hill AR. Hemodynamic confirmation of septic shock in disseminated tuberculosis. Crit Care Med. 1992;20(6):901-903. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1597048.
  107. Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine. 1991;70(6):384-397. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1956280.
  108. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-1481. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22010913.
  109. Whalen C, Horsburgh CR, Jr., Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS. 1997;11(4):455-460. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9084792.
  110. Kourbatova EV, Leonard MK, Jr., Romero J, Kraft C, del Rio C, Blumberg HM. Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US. Eur J Epidemiol. 2006;21(9):715-721. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17072539.
  111. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741-1751. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15496623.
  112. Lewis JJ, Charalambous S, Day JH, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med. 2009;180(12):1271-1278. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19745207.
  113. Cavanaugh JS, Modi S, Musau S, et al. Comparative yield of different diagnostic tests for tuberculosis among people living with HIV in western Kenya. PLoS One. 2016;11(3):e0152364. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27023213.
  114. Henostroza G, Harris JB, Chitambi R, et al. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis. 2016;20(8):1033-1039. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27393536.
  115. Arpagaus A, Franzeck FC, Sikalengo G, et al. Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort. PLoS One. 2020;15(3):e0229875. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32130279.
  116. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993;96(1):1-11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8429569.
  117. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9(3):173-184. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19246021.
  118. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med. 2009;180(9):903-908. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19628775.
  119. Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis. 1992;15(4):601-605. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1420673.
  120. Razack R, Louw M, Wright CA. Diagnostic yield of fine needle aspiration biopsy in HIV-infected adults with suspected mycobacterial lymphadenitis. S Afr Med J. 2013;104(1):27-28. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24388082.
  121. Cheng VC, Yew WW, Yuen KY. Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis. 2005;24(11):711-720. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16283213.
  122. Diedrich CR, O'Hern J, Gutierrez MG, et al. Relationship between HIV coinfection, interleukin 10 production, and Mycobacterium tuberculosis in human lymph node granulomas. J Infect Dis. 2016;214(9):1309-1318. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27462092.
  123. Heysell SK, Moll AP, Gandhi NR, et al. Extensively drug-resistant Mycobacterium tuberculosis from aspirates, rural South Africa. Emerg Infect Dis. 2010;16(3):557-560. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20202446.
  124. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20825313.
  125. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess. 2007;11(3):1-196. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17266837.
  126. Forbes BA, Hall GS, Miller MB, et al. Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin Microbiol Rev. 2018. Available at: https://cmr.asm.org/content/cmr/31/2/e00038-17.full.pdf.
  127. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. 2011. Available at: https://www.who.int/publications/i/item/9789241501545.
  128. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24448973.
  129. Luetkemeyer AF, Kendall MA, Wu X, et al. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014;52(4):1052-1059. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24430455.
  130. Lawn SD, Kerkhoff AD, Vogt M, Wood R. HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays. BMC Med. 2013;11:231. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24168211.
  131. Maynard-Smith L, Larke N, Peters JA, Lawn SD. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis. 2014;14:709. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25599808.
  132. Rahman SMM, Maliha UT, Ahmed S, et al. Evaluation of Xpert MTB/RIF assay for detection of Mycobacterium tuberculosis in stool samples of adults with pulmonary tuberculosis. PLoS One. 2018;13(9):e0203063. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30212505.
  133. Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med. 2017;377(11):1043-1054. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28902596.
  134. Drain PK, Losina E, Coleman SM, et al. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014;14:110. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24571362.
  135. Drain PK, Losina E, Coleman SM, et al. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis. J Acquir Immune Defic Syndr. 2015;68(3):274-280. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25415288.
  136. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013;13:407. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24004840.
  137. Broger T, Moyoyeta M, Kerkhoff AD, Denkinger CM, Moreau E. Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM. The Lancet: Infectious Diseases. 2020;20(1):22-23. Available at: https://pubmed.ncbi.nlm.nih.gov/31876492.
  138. World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV, 2019 Update. 2019. Available at: https://www.who.int/publications/i/item/9789241550604.
  139. Quinn CM, Kagimu E, Okirworth M, et al. Fujifilm SILVAMP TB LAM assay on cerebrospinal fluid for the detection of tuberculous meningitis in adults with Human Immunodeficiency Virus. Clin Infect Dis. 2021;73(9):e3428-e3434. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33388751.
  140. Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28344011.
  141. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123-134. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18626051.
  142. Centers for Disease Control and Prevention. Surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis. 2022. Available at: https://www.cdc.gov/tb/publications/letters/2022/surv-def-xdr.html.
  143. Viney K, Linh NN, Gegia M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J. 2021;57(4). Available at: https://www.ncbi.nlm.nih.gov/pubmed/33833074.
  144. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):80-86. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19833824.
  145. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355(15):1539-1550. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17035648.
  146. Walker TM, Miotto P, Koser CU, et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis. Lancet Microbe. 2022;3(4):e265-e273. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35373160.
  147. Heysell SK, Houpt ER. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn. 2012;12(4):395-405. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22616704.
  148. Barnard M, Warren R, Gey Van Pittius N, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med. 2012;186(12):1298-1305. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23087027.
  149. Rice JP, Seifert M, Moser KS, Rodwell TC. Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting. PLoS One. 2017;12(10):e0186139. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29016684.
  150. Ocheretina O, Byrt E, Mabou MM, et al. False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis. 2016;85(1):53-55. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26915638.
  151. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27516382.
  152. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705-1718. Available at: https://pubmed.ncbi.nlm.nih.gov/33951360/.
  153. Pettit AC, Phillips PPJ, Kurbatova E, et al. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31/A5349). Clin Infect Dis. 2023;76(3):e580-e589. Available at: https://pubmed.ncbi.nlm.nih.gov/36041016/.
  154. Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(8):285-289. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35202353.
  155. Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for use of video directly observed therapy during tuberculosis treatment - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(12):313-316. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36952279.
  156. Burzynski J, Mangan JM, Lam CK, et al. In-person vs electronic directly observed therapy for tuberculosis treatment adherence: a randomized noninferiority trial. JAMA Netw Open. 2022;5(1):e2144210. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35050357.
  157. Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7):e1002595. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29969463.
  158. Story A, Aldridge RW, Smith C, Garber E, Hall J, Ferenando G. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicenter, analyst-blinded randomized, controlled superiority trial. Lancet. 2019;393(10177):1216-1224. Available at: https://pubmed.ncbi.nlm.nih.gov/30799062.
  159. Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019;16(10):e1002891. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31584944.
  160. Centers for Disease Control and Prevention. Implementing an electronic directly observed therapy (eDOT) Program: A Toolkit for Tuberculosis (TB) Programs. 2017. Available at: https://www.cdc.gov/tb/publications/guidestoolkits/tbedottoolkit.htm.
  161. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010;181(7):743-751. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19965813.
  162. Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731-736. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14986259.
  163. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41(1):83-91. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15937767.
  164. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50(9):1288-1299. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20353364.
  165. Vashishtha R, Mohan K, Singh B, et al. Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study. BMC Infect Dis. 2013;13:468. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24099345.
  166. Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis. 2014;59(12):1798-1804. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25156114.
  167. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843-1847. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10359410.
  168. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173(3):350-356. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16109981.
  169. Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Intern Med. 2018;178(4):485-493. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29507938.
  170. Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708-1715. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30397355.
  171. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR11):1-77. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
  172. el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26(5):1148-1158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9597244.
  173. Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995;332(12):779-784. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7862181.
  174. Jullien S, Ryan H, Modi M, Bhatia R. Six months therapy for tuberculous meningitis. Cochrane Database Syst Rev. 2016;9(9):CD012091. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27581996.
  175. Cresswell FV, Meya DB, Kagimu E, et al. High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)-positive Ugandan adults: a Phase II open-label randomized controlled trial. Clin Infect Dis. 2021;73(5):876-884. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33693537.
  176. Smith AGC, Gujabidze M, Avaliani T, et al. Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens. Int J Tuberc Lung Dis. 2021;25(8):632-639. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34330348.
  177. Huynh J, Donovan J, Phu NH, Nghia HDT, Thuong NTT, Thwaites GE. Tuberculous meningitis: progress and remaining questions. Lancet Neurol. 2022;21(5):450-464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35429482.
  178. Dian S, Yunivita V, Ganiem AR, et al. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018;62(12). Available at: https://www.ncbi.nlm.nih.gov/pubmed/30224533.
  179. Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016;374(2):124-134. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26760084.
  180. Te Brake L, Dian S, Ganiem AR, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents. 2015;45(5):496-503. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25703312.
  181. Yunivita V, Dian S, Ganiem AR, et al. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents. 2016;48(4):415-421. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27526979.
  182. Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39-49. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28100438.
  183. Ruslami R, Ganiem AR, Aarnoutse RE, van Crevel R, study t. Rifampicin and moxifloxacin for tuberculous meningitis--authors' reply. Lancet Infect Dis. 2013;13(7):570. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23809224.
  184. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27121755.
  185. Wang W, Gao J, Liu J, Qi J, Zhang Q. Clinical efficacy of dexamethasone in the treatment of patients with tuberculous meningitis: a meta-analysis. Contrast Media Mol Imaging. 2022;2022:2180374. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35418812.
  186. Donovan J, Bang ND, Imran D, et al. Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults. N Engl J Med. 2023;389(15):1357-1367. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37819954.
  187. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121-1130. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25178809.
  188. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017;9:CD000526. Available at: http://www.ncbi.nlm.nih.gov/pubmed/28902412.
  189. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis. 2014;14(7):563-571. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24810491.
  190. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22010914.
  191. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697-706. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20181971.
  192. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007;175(11):1199-1206. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17290042.
  193. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374-1383. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21596680.
  194. Li L, Li J, Chai C, et al. Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2021;14(6):670-679. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34239668.
  195. Chelkeba L, Fekadu G, Tesfaye G, Belayneh F, Melaku T, Mekonnen Z. Effects of time of initiation of antiretroviral therapy in the treatment of patients with HIV/TB co-infection: A systemic review and meta-analysis. Ann Med Surg (Lond). 2020;55:148-158. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32477514.
  196. Burke RM, Rickman HM, Singh V, et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis. J Int AIDS Soc. 2021;24(7):e25772. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34289243.
  197. Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915-1925. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30428290.
  198. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56(3):450-460. Available at: https://pubmed.ncbi.nlm.nih.gov/23097584/.
  199. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364(9441):1244-1251. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15464185.
  200. Johnson JL, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis. 2000;4(11):1032-1040. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11092715.
  201. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22 Suppl 1:S15-21; discussion S21-12. Available at: https://pubmed.ncbi.nlm.nih.gov/8785251/.
  202. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007(4):CD005159. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17943842.
  203. Singh R, Marshall N, Smith CJ, et al. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients. AIDS. 2013;27(3):481-484. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23014518.
  204. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154(5):1462-1467. Available at: https://pubmed.ncbi.nlm.nih.gov/8912765/.
  205. Kendall MA, Lalloo U, Fletcher CV, et al. Safety and pharmacokinetics of double-dose lopinavir/ritonavir + rifampin versus lopinavir/ritonavir + daily rifabutin for treatment of human immunodeficiency virus-tuberculosis coinfection. Clin Infect Dis. 2021;73(4):706-715. Available at: https://pubmed.ncbi.nlm.nih.gov/34398956/.
  206. Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670-1678. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30815689.
  207. Martin TCS, Hill LA, Tang ME, Balcombe SM. Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study. Int J Infect Dis. 2020;100:470-472. Available at: https://pubmed.ncbi.nlm.nih.gov/32979587/.
  208. Liou BH, Cheng CN, Lin YT, et al. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. J Int AIDS Soc. 2021;24(11):e25844. Available at: https://pubmed.ncbi.nlm.nih.gov/34822220/.
  209. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009;14(5):687-695. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19704172.
  210. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother. 2009;53(3):863-868. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19124658.
  211. Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586-593. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23592830.
  212. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20(1):131-132. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16327334.
  213. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300(5):530-539. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18677025.
  214. Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2019;68(3):446-452. Available at: https://pubmed.ncbi.nlm.nih.gov/30084943/.
  215. Podany AT, Pham M, Sizemore E, et al. Efavirenz pharmacokinetics and human immunodeficiency virus type 1 (HIV-1) viral suppression among patients receiving tuberculosis treatment containing daily high-dose rifapentine. Clin Infect Dis. 2022;75(4):560-566. Available at: https://pubmed.ncbi.nlm.nih.gov/34918028/.
  216. Yee KL, Khalilieh SG, Sanchez RI, et al. The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig. 2017;37(7):659-667. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28353169.
  217. Khalilieh SG, Yee KL, Sanchez RI, et al. Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects. J Clin Pharmacol. 2018;58(8):1044-1052. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29723418.
  218. Janssen Therapeutics. Edurant [package insert]. 2021. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf.
  219. Kakuda TN, Woodfall B, De Marez T, et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother. 2014;69(3):728-734. Available at: https://pubmed.ncbi.nlm.nih.gov/24155058/.
  220. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21-27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23075918.
  221. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70(4):549-556. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30918967.
  222. Griesel R, Hill A, Meintjes G, Maartens G. Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. Wellcome Open Res. 2021;6:1. Available at: https://pubmed.ncbi.nlm.nih.gov/33954265/.
  223. Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis. 2014;14(6):459-467. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24726095.
  224. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852-2856. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19433563.
  225. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. 2011;51(10):1376-1402. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21209233.
  226. Custodio JM, West SK, Collins S, et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Presented at: Conference on Retroviruses and Opportunistic Infections; 2018. Boston, MA. Available at: https://www.croiconference.org/abstract/pharmacokinetics-bictegravir-administered-twice-daily-combination-rifampin.
  227. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50(4):229-244. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21348537.
  228. Toomey CB, Lee J, Spencer DB. Rifabutin-cobicistat drug interaction resulting in severe bilateral panuveitis. Case Rep Ophthalmol. 2020;11(1):156-160. Available at: https://pubmed.ncbi.nlm.nih.gov/32399018/.
  229. Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61(10). Available at: https://pubmed.ncbi.nlm.nih.gov/28739783/.
  230. Rajoli RKR, Curley P, Chiong J, et al. Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis. 2019;219(11):1735-1742. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30566691.
  231. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50(10):3336-3342. Available at: https://pubmed.ncbi.nlm.nih.gov/17005814/.
  232. Justesen US, Andersen AB, Klitgaard NA, Brøsen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis. 2004;38(3):426-429. Available at: https://pubmed.ncbi.nlm.nih.gov/14727216/.
  233. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(5):1553-1560. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15105105.
  234. Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014;53(6):489-507. Available at: https://pubmed.ncbi.nlm.nih.gov/24777631/.
  235. Ebrahim I, Maartens G, Wiesner L, Orrell C, Smythe W, McIlleron H. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. J Antimicrob Chemother. 2020;75(4):1019-1025. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31942627.
  236. Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother. 2011;55(7):3195-3200. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21537021.
  237. Food and Drug Adminstration. Kaletra [package insert]. 2020. Available at: https://www.rxabbvie.com/pdf/kaletratabpi.pdf.
  238. Bristol-Myers Squibb. Atazanavir [package insert]. 2018. Available at: https://packageinserts.bms.com/pi/pi_reyataz.pdf.
  239. Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54(10):4440-4445. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20660678.
  240. Ford SL, Chen YC, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother. 2008;52(2):534-538. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18056271.
  241. Lin HC, Lu PL, Chang CH. Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra). Eye (Lond). 2007;21(12):1540-1541. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17962822.
  242. Lan NT, Thu NT, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9(1):e84866. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24465443.
  243. Naiker S, Connolly C, Wiesner L, et al. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. BMC Pharmacol Toxicol. 2014;15:61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25406657.
  244. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48(10):1471-1474. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19368504.
  245. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49(9):1305-1311. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19807276.
  246. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528-534. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12241657.
  247. Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. The Journal of Infectious Diseases. 2012;206(7):1030-1040. Available at: https://pubmed.ncbi.nlm.nih.gov/22850121.
  248. Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC. Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis. Eur Respir J. 2011;37(2):376-383. Available at: https://pubmed.ncbi.nlm.nih.gov/20516049/.
  249. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839-854. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24846578.
  250. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196 Suppl 1:S63-75. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17624828.
  251. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99(2):465-471. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1824929.
  252. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis. 2010;50(6):833-839. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20156055.
  253. Tahaoglu K, Atac G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2001;5(1):65-69. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11263519.
  254. Abbara A, Chitty S, Roe JK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17(1):231. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28340562.
  255. Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J Tuberc Lung Dis. 2011;15(12):1649-1657. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22118173.
  256. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2019. 2019. Available at: https://www.cdc.gov/tb/statistics/reports/2019/default.htm.
  257. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):223-234. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27865891.
  258. van der Heijden YF, Karim F, Mufamadi G, et al. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis. 2017;21(6):670-676. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28482962.
  259. Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265-275. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29595509.
  260. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 2018. Available at: http://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf.
  261. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. Available at: https://www.who.int/publications/i/item/9789241550529.
  262. Vogensen VB, Bolhuis MS, Sturkenboom MGG, et al. Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid-resistant/intolerant tuberculosis patients. Antimicrob Agents Chemother. 2022;66(2):e0182921. Available at: https://pubmed.ncbi.nlm.nih.gov/34807758/.
  263. Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother. 2007;51(8):2861-2866. Available at: https://pubmed.ncbi.nlm.nih.gov/17517835/.
  264. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001-1007. Available at: https://pubmed.ncbi.nlm.nih.gov/17879915/.
  265. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32130813.
  266. Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810-823. Available at: https://pubmed.ncbi.nlm.nih.gov/36053506/.
  267. Nyang'wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117-128. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37980911.
  268. Nyang'wa BT, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331-2343. Available at: https://pubmed.ncbi.nlm.nih.gov/36546625/.
  269. Labuda SM, Seaworth B, Dasgupta S, Goswami ND, Team BPAMP. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2024;12(2):e5-e6. Available at: https://www.ncbi.nlm.nih.gov/pubmed/38043563.
  270. Haley CA, Schechter MC, Ashkin D, et al. Implementation of BPaL in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease. Clin Infect Dis. 2023. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37249079.
  271. Centers for Disease Control and Prevention. Provisional CDC guidance for the use of pretomanid as part of a regimen [bedaquiline, pretomanid, and linezolid (BPaL)] to treat drug-resistant tuberculosis disease. 2024. Accessed February 21. Available at: https://www.cdc.gov/tb/topic/drtb/bpal/default.htm#print.
  272. World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. 2022. Accessed May 12. Available at: https://www.who.int/publications/i/item/9789240065116.
  273. Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-834. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30215381.
  274. Mok J, Lee M, Kim DK, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522-1530. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36522208.
  275. Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022;400(10366):1858-1868. Available at: https://pubmed.ncbi.nlm.nih.gov/36368336/.
  276. Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30865791.
  277. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment - drug-resistant tuberculosis treatment. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32603040.
  278. Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am J Respir Crit Care Med. 2022;205(10):1214-1227. Available at: https://pubmed.ncbi.nlm.nih.gov/35175905/.
  279. Barilar I, Fernando T, Utpatel C, et al. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study. Lancet Infect Dis. 2023. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37956677.
  280. Perumal R, Bionghi N, Nimmo C, et al. Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2023;62(6). Available at: https://www.ncbi.nlm.nih.gov/pubmed/37945030.
  281. Nimmo C, Bionghi N, Cummings MJ, et al. Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. Lancet Microbe. 2024;5(2):e164-e172. Available at: https://www.ncbi.nlm.nih.gov/pubmed/38215766.
  282. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780-2787. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23571542.
  283. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406-6412. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25114140.
  284. Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016;71(4):1037-1040. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26747099.
  285. Brust JCM, Gandhi NR, Wasserman S, et al. Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2021;73(11):2083-2092. Available at: https://pubmed.ncbi.nlm.nih.gov/33882121/.
  286. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615-1627. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15280772.
  287. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5(6):361-373. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15919622.
  288. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009;30(4):797-810, x. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19925968.
  289. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516-523. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18652998.
  290. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251-261. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20334848.
  291. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis. 2007;11(12):1282-1289. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18229435.
  292. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009;48(11):e96-107. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19405867.
  293. Lawn SD, Wood R. Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS. 2007;21(17):2362-2363. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18090294.
  294. Sonderup MW, Wainwright H, Hall P, Hairwadzi H, Spearman CW. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology. 2015;61(5):1721-1729. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25644940.
  295. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10(6):1077-1099. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26059627.
  296. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158(1):157-161. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9655723.
  297. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59(8):704-707. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15282393.
  298. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004;39(11):1709-1712. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15578375.
  299. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21(3):335-341. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17255740.
  300. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006;53(6):357-363. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16487593.
  301. Serra FC, Hadad D, Orofino RL, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz J Infect Dis. 2007;11(5):462-465. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17962870.
  302. Olalla J, Pulido F, Rubio R, et al. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis. 2002;6(1):71-75. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11931404.
  303. Huyst V, Lynen L, Bottieau E, Zolfo M, Kestens L, Colebunders R. Immune reconstitution inflammatory syndrome in an HIV/TB co-infected patient four years after starting antiretroviral therapy. Acta Clin Belg. 2007;62(2):126-129. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17547295.
  304. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10(3):417-422. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15918332.
  305. Luetkemeyer AF, Kendall MA, Nyirenda M, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014;65(4):423-428. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24226057.
  306. Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS One. 2013;8(5):e63541. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23691062.
  307. Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis. 2009;48(5):667-676. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19191655.
  308. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381-2390. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20808204.
  309. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923-925. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6403136.
  310. Xie YL, Ita-Nagy F, Chen RY, et al. Neurotuberculosis: control of steroid-refractory paradoxical inflammatory reaction with ruxolitinib. Open Forum Infect Dis. 2019;6(10):ofz422. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31687418.
  311. Brunel AS, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS. 2012;26(16):2110-2112. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22874513.
  312. Hsu DC, Faldetta KF, Pei L, et al. A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS. Clin Infect Dis. 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26394669.
  313. Fourcade C, Mauboussin JM, Lechiche C, Lavigne JP, Sotto A. Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis. AIDS Patient Care STDS. 2014;28(11):567-569. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25285462.
  314. Keeley AJ, Parkash V, Tunbridge A, et al. Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases. Int J STD AIDS. 2020;31(8):808-812. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32631210.
  315. Marais BJ, Cheong E, Fernando S, et al. Use of infliximab to treat paradoxical tuberculous meningitis reactions. Open Forum Infect Dis. 2021;8(1):ofaa604. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33542942.
  316. Abo YN, Curtis N, Osowicki J, et al. Infliximab for paradoxical reactions in pediatric central nervous system tuberculosis. J Pediatric Infect Dis Soc. 2021;10(12):1087-1091. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34608937.
  317. van Toorn R, Rabie H, Dramowski A, Schoeman JF. Neurological manifestations of TB-IRIS: a report of 4 children. Eur J Paediatr Neurol. 2012;16(6):676-682. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22658306.
  318. John L, Baalwa J, Kalimugogo P, et al. Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?'. AIDS. 2005;19(17):2049-2050. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16260919.
  319. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect. 2003;79(4):337-338. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12902592.
  320. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: the role of macrophages. AIDS. 2009;23(1):143-145. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19050399.
  321. Chen WL, Lin YF, Tsai WC, Tsao YT. Unveiling tuberculous pyomyositis: an emerging role of immune reconstitution inflammatory syndrome. Am J Emerg Med. 2009;27(2):251 e251-252. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19371548.
  322. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003;37(1):101-112. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12830415.
  323. Vega V, Rodríguez S, Van der Stuyft P, Seas C, Otero L. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax. 2021;76(5):494-502. Available at: https://pubmed.ncbi.nlm.nih.gov/33547088/.
  324. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687-1693. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11728545.
  325. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691-703. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20121433.
  326. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004;170(12):1360-1366. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15477492.
  327. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Jr., Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. 2000;356(9240):1470-1474. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11081529.
  328. Haller L, Sossouhounto R, Coulibaly IM, Dosso M, al e. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy. 1999;45(6):452-465. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10567776.
  329. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2(12):e710-716. Available at: https://pubmed.ncbi.nlm.nih.gov/25433626/.
  330. Mofenson LM, Rodriguez EM, Hershow R, et al. Mycobacterium tuberculosis infection in pregnant and nonpregnant women infected with HIV in the Women and Infants Transmission Study. Arch Intern Med. 1995;155(10):1066-1072. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7748050.
  331. Eriksen NL, Helfgott AW. Cutaneous anergy in pregnant and nonpregnant women with human immunodeficiency virus. Infect Dis Obstet Gynecol. 1998;6(1):13-17. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9678142.
  332. Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet. 1994;44(2):119-124. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7911094.
  333. Jana N, Vasishta K, Saha SC, Ghosh K. Obstetrical outcomes among women with extrapulmonary tuberculosis. N Engl J Med. 1999;341(9):645-649. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10460815.
  334. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370(23):2211-2218. Available at: https://pubmed.ncbi.nlm.nih.gov/24897084/.
  335. Jonnalagadda S, Lohman Payne B, Brown E, et al. Latent tuberculosis detection by interferon gamma release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their children. J Infect Dis. 2010;202(12):1826-1835. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21067370.
  336. Jonnalagadda SR, Brown E, Lohman-Payne B, et al. Consistency of Mycobacterium tuberculosis-specific interferon-gamma responses in HIV-1-infected women during pregnancy and postpartum. Infect Dis Obstet Gynecol. 2012;2012:950650. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22496602.
  337. Bhosale R, Alexander M, Deshpande P, et al. Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India. Int J Infect Dis. 2021;112:205-211. Available at: https://pubmed.ncbi.nlm.nih.gov/34517050/.
  338. Kaplan SR, Escudero JN, Mecha J, et al. Interferon gamma release assay and tuberculin skin test performance in pregnant women living with and without HIV. J Acquir Immune Defic Syndr. 2022;89(1):98-107. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34629414.
  339. Lighter-Fisher J, Surette AM. Performance of an interferon-gamma release assay to diagnose latent tuberculosis infection during pregnancy. Obstet Gynecol. 2012;119(6):1088-1095. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22569120.
  340. Mathad JS, Bhosale R, Balasubramanian U, et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193(12):1421-1428. Available at: https://pubmed.ncbi.nlm.nih.gov/26765255/.
  341. Mathad JS, Bhosale R, Sangar V, et al. Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high-burden setting. PLoS One. 2014;9(3):e92308. Available at: https://pubmed.ncbi.nlm.nih.gov/24658103/.
  342. LaCourse SM, Cranmer LM, Matemo D, et al. Effect of pregnancy on interferon gamma release assay and tuberculin skin test detection of latent TB infection among HIV-infected women in a high burden setting. J Acquir Immune Defic Syndr. 2017;75(1):128-136. Available at: https://pubmed.ncbi.nlm.nih.gov/28141782/.
  343. Weinberg A, Aaron L, Montepiedra G, et al. Effects of pregnancy and isoniazid preventive therapy on Mycobacterium tuberculosis interferon gamma response assays in women with HIV. Clin Infect Dis. 2021;73(9):e3555-e3562. Available at: https://pubmed.ncbi.nlm.nih.gov/32720695/.
  344. Gupta A, Montepiedra G, Aaron L, Theron G. isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381:1333-1346. Available at: https://pubmed.ncbi.nlm.nih.gov/31577875.
  345. Salazar-Austin N, Cohn S, Lala S, et al. Isoniazid preventive therapy and pregnancy outcomes in women living with human immunodeficiency virus in the Tshepiso cohort. Clin Infect Dis. 2020;71(6):1419-1426. Available at: https://pubmed.ncbi.nlm.nih.gov/31631221/.
  346. Kalk E, Heekes A, Mehta U, et al. Safety and effectiveness of isoniazid preventive therapy in pregnant women living with human immunodeficiency virus on antiretroviral therapy: An Observational Study Using Linked Population Data. Clin Infect Dis. 2020;71(8):e351-e358. Available at: https://pubmed.ncbi.nlm.nih.gov/31900473/.
  347. Taylor AW, Mosimaneotsile B, Mathebula U, et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol. 2013;2013:195637. Available at: https://pubmed.ncbi.nlm.nih.gov/23533318/.
  348. Hamada Y, Figueroa C, Martín-Sánchez M, Falzon D, Kanchar A. The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. Eur Respir J. 2020;55(3). Available at: https://pubmed.ncbi.nlm.nih.gov/32217619/.
  349. Gupta A, Hughes MD, Cruz JL, et al. Adverse pregnancy outcomes among HIV-infected women taking isoniazid preventive therapy during the first trimester. Clin Infect Dis. 2023. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37768207.
  350. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10(7):489-498. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20610331.
  351. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis. 2007;45(2):241-249. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17578786.
  352. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182(8):1080-1085. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20558626.
  353. Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. Obstet Gynecol. 2020;135(6):1444-1453. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32459437.
  354. Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clin Infect Dis. 2022;74(9):1604-1613. Available at: https://pubmed.ncbi.nlm.nih.gov/34323955/.
  355. Moro RN, Scott NA, Vernon A, et al. Exposure to latent tuberculosis treatment during pregnancy. the PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018;15(5):570-580. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29393655.
  356. Food and Drug Administration. PRIFTIN (rifapentine). 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf.
  357. Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and safety of three months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clin Infect Dis. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34323955.
  358. Hoffmann CJ, Variava E, Rakgokong M, et al. High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS One. 2013;8(4):e62211. Available at: https://pubmed.ncbi.nlm.nih.gov/23614037/.
  359. LaCourse SM, Cranmer LM, Matemo D, et al. Tuberculosis case finding in HIV-infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. J Acquir Immune Defic Syndr. 2016;71(2):219-227. Available at: https://pubmed.ncbi.nlm.nih.gov/26334736/.
  360. Kosgei RJ, Szkwarko D, Callens S, et al. Screening for tuberculosis in pregnancy: do we need more than a symptom screen? Experience from western Kenya. Public Health Action. 2013;3(4):294-298. Available at: https://pubmed.ncbi.nlm.nih.gov/26393049/.
  361. Committee Opinion. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol. 2017;130(4):e210-e216. Available at https://pubmed.ncbi.nlm.nih.gov/28937575.
  362. Mnyani CN, McIntyre JA. Tuberculosis in pregnancy. BJOG. 2011;118(2):226-231. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21083862.
  363. Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am. 1997;24(3):659-673. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9266585.
  364. Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf. 2001;24(7):553-565. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11444726.
  365. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A population-based case-control study of the safety of oral anti-tuberculosis drug treatment during pregnancy. Int J Tuberc Lung Dis. 2001;5(6):564-568. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11409585.
  366. Efferen LS. Tuberculosis and pregnancy. Curr Opin Pulm Med. 2007;13(3):205-211. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17414128.
  367. Vilarinho LC. Congenital tuberculosis: a case report. Braz J Infect Dis. 2006;10(5):368-370. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17293929.
  368. Lee LH, LeVea CM, Graman PS. Congenital tuberculosis in a neonatal intensive care unit: case report, epidemiological investigation, and management of exposures. Clin Infect Dis. 1998;27(3):474-477. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9770143.
  369. Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: congenital tuberculosis. N Engl J Med. 1994;330(15):1051-1054. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8127333.
  370. Rinsky JL, Farmer D, Dixon J, et al. Notes from the field: contact investigation for an infant with congenital tuberculosis infection - North Carolina, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(23):670-671. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29902167.
  371. Chang CW, Wu PW, Yeh CH, Wong KS, Wang CJ, Chang CC. Congenital tuberculosis: case report and review of the literature. Paediatr Int Child Health. 2018;38(3):216-219. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28421876.
  372. Stuart RL, Lewis A, Ramsden CA, Doherty RR. Congenital tuberculosis after in-vitro fertilisation. Med J Aust. 2009;191(1):41-42. Available at: https://pubmed.ncbi.nlm.nih.gov/19580539/.
  373. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis. 2004;8(1):59-69. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14974747.
  374. Adhikari M, Pillay T, Pillay DG. Tuberculosis in the newborn: an emerging disease. Pediatr Infect Dis J. 1997;16(12):1108-1112. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9427454.
  375. Franks AL, Binkin NJ, Snider DE, Jr., Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104(2):151-155. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2495549.
  376. Dlodlo RA, Brigden G, Heldal E, et al. Management of tuberculosis: a guide to essential practice. Paris, France: International Union Against Tuberculosis and Lung Disease; October 2019. Available at: https://theunion.org/sites/default/files/2020-08/TheUnion_Orange_2019.pdf.
  377. Dluzniewski A, Gastol-Lewinska L. The search for teratogenic activity of some tuberlostatic drugs. Diss Pharm Pharmacol. 1971;23:383-392.
  378. Lotia Farrukh I, Lachenal N, Adenov MM, et al. Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs. Clin Infect Dis. 2023. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37606512.
  379. Lessnau KD, Qarah S. Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. Chest. 2003;123(3):953-956. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12628902.
  380. Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis. 2005;40(11):1689-1692. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15889370.
  381. Alene KA, Murray MB, van de Water BJ, et al. Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(6):e2216527. Available at: https://pubmed.ncbi.nlm.nih.gov/35687333/.
  382. Loveday M, Hughes J, Sunkari B, et al. Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa. Clinical Infectious Diseases. 2020;72(7):1158-1168. Available at: https://pubmed.ncbi.nlm.nih.gov/32141495.
  383. Court R, Gausi K, Mkhize B, et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol. 2022;88(8):3548-3558. Available at: https://pubmed.ncbi.nlm.nih.gov/35526837/.
  384. Jaspard M, Elefant-Amoura E, Melonio I, De Montgolfier I, Veziris N, Caumes E. Bedaquiline and linezolid for extensively drug-resistant tuberculosis in pregnant woman. Emerg Infect Dis. 2017;23(10):1731-1732. Available at: https://pubmed.ncbi.nlm.nih.gov/28792382/.
  385. Fujimori H, et al. The effect of tuberculostatics on the fetus: an experimental production of congenital anomaly in rats by ethionamide. Proc Congen Anom Res Assoc Jpn. 1965;5:34-35.
  386. Takekoshi S. Effects of hydroxymethylpyrimidine on isoniazid- and ethionamide-induced teratosis. Gunma J Med Sci. 1965;14:233-244.
  387. Khan I, Azam A. Study of teratogenic activity of trifluoperazine, amitriptyline, ethionamide and thalidomide in pregnant rabbits and mice. Proc Eur Soc Study Drug Toxic. 1969;10:235-242.
  388. Potworowska M, Sianoz-Ecka E, Szufladowica R. Treatment with ethionamide in pregnancy. Pol Med J. 1966;5(5):1152-1158. Available at: https://www.ncbi.nlm.nih.gov/pubmed/5958801.
  389. Schaefer C, Amoura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol. 1996;69(2):83-89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8902438.
  390. Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018;125(9):1069-1076. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29319210.
  391. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42(6):1336-1339. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9624471.
  392. Ziv A, Masarwa R, Perlman A, Ziv D, Matok I. Pregnancy Outcomes Following exposure to quinolone antibiotics - a systematic-review and meta-analysis. Pharm Res. 2018;35(5):109. Available at: https://pubmed.ncbi.nlm.nih.gov/29582196/.
  393. Acar S, Keskin-Arslan E, Erol-Coskun H, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. Reprod Toxicol. 2019;85:65-74. Available at: https://pubmed.ncbi.nlm.nih.gov/30738954/.
  394. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107(5):1120-1138. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16648419.
  395. ZYVOX [package insert]. Food and Drug Administration. 2008. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021130s016,021131s013,021132s014lbl.pdf.
  396. Van Kampenhout E, Bolhuis MS, Alffenaar JC, et al. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3). Available at: https://pubmed.ncbi.nlm.nih.gov/28331037/.
  397. Acquah R, Mohr-Holland E, Daniels J, et al. Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: A Report of Five Patients. Pediatr Infect Dis J. 2021;40(5):e191-e192. Available at: https://pubmed.ncbi.nlm.nih.gov/33847295/.
  398. PRETOMANID [package insert]. Food and Drug Administration. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212862s004lbl.pdf.
  399. Varpela E. On the effect exerted by first-line tuberculosis medicines on the foetus. Acta Tuberc Pneumol Scand. 1964;45:53-69. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14209270.

Treating Latent TB Infection

Recommendations for Treating LTBI to Prevent TB Disease in People with HIV

Indications

  • Positive screening testa for LTBI (≥5 mm of induration at 48–72 hours in people with HIV or positive IGRA) regardless of BCG status, no evidence of active TB disease, and no prior history of treatment for active disease or latent TB infection (AI).
  • Close contact with a person with infectious TB (such as someone who has shared air space, such as in a household or close congregate setting, with a person with active pulmonary TB according to the Centers for Disease Control and Prevention Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis) regardless of screening test result and CD4 count (AII).

Preferred Therapy

  • Isoniazid 15 mg/kg PO once weekly (900 mg maximum) plus rifapentine (see weight-based dosing below) PO once weekly plus pyridoxine 50 mg PO once weekly (3HP) for 12 weeks (AI). Note: 3HP is recommended only for virally-suppressed patients receiving an efavirenz-, raltegravir-, or once-daily dolutegravir-based ARV regimen (AII).
    • Rifapentine Weekly Dose (maximum 900 mg)
      • Weighing 25.132 kg: 600 mg
      • Weighing 32.1–49.9 kg: 750 mg
      • Weighing ≥50.0 kg: 900 mg
  • Isoniazid 300 mg PO daily plus rifampin 600 mg PO daily plus pyridoxine 25–50 mg PO daily (AI) for 3 months (3HR). See the Dosing Recommendations for use of ARV and Anti-TB Drugs When Treating Latent TB table for the list of ARV drugs not recommended for use with rifampin (e.g., protease inhibitors, bictegravir) and those which require dosage adjustment (i.e., raltegravir, dolutegravir, or maraviroc).

Alternative Therapy

  • Isoniazid 300 mg PO daily plus pyridoxine 25–50 mg PO daily for 6–9 months (AII) or
  • Rifampin 600 mg PO daily for 4 months (BI) (4R)
  • Isoniazid 300 mg PO daily plus rifapentine (see weight-based dosing below) PO daily plus pyridoxine 25–50 mg PO daily for 4 weeks (BI) (1HP) Note: 1HP is recommended only for patients receiving an efavirenz-based ARV regimen (AI).
    • Rifapentine Daily Dose (maximum 600 mg)
      • Weighing <35 kg: 300 mg
      • Weighing 35–45 kg: 450 mg
      • Weighing >45 kg: 600 mg
  • For people exposed to drug-resistant TB, select drugs for prevention of TB after consultation with experts and with public health authorities (AIII).

Pregnancy Considerations

  • 4R and 3HR are acceptable alternative regimens for pregnant people with HIV (BIII).
  • For pregnant people receiving effective ART and without close household contact with infectious TB or recent test for TB infection (TST or IGRA) conversion from negative to positive, therapy for LTBI may be deferred until after delivery (BIII).
  • Although rifampin generally is considered safe in pregnancy, data on the use of rifapentine are extremely limited and its use in pregnant people is not currently recommended (BIII).

Additional Considerations

  • Deferring ART until after completion of treatment for LTBI is not recommended (AI).
  • Given the important drug–drug interactions between rifamycins and several antiretroviral (ARV) agents, selection of an LTBI regimen will depend on a patient’s current or planned ARV regimen.
a Screening tests for LTBI include a tuberculin skin test (TST) or interferon-gamma release assay (IGRA); see text for details regarding these tests.

Key: H = Isoniazid; P = Rifapentine; R = Rifampin; ARV = antiretroviral; CDC = Centers for Disease Control and Prevention; CD4 = CD4 T lymphocyte; CNS = central nervous system; DOT = directly observed therapy; IRIS = immune reconstitution inflammatory syndrome; IPT = isoniazid preventive therapy; LTBI = latent tuberculosis infection; PI = protease inhibitor; PO = orally; TB = tuberculosis
Dosing Recommendations for Use of ARV and Anti-TB Drugs When Treating Latent TB Infection
TB DrugARV DrugsDose of TB Drug
Isoniazid (INH)
  • All ARVs
  • Note: for information on coadministration of ARVs with rifampin or rifapentine, see entries below

Use INH with pyridoxine 25–50 mg PO daily (50 mg once weekly if used with 3HP)

For 3HP (weekly INH + rifapentine x 12 weeks)

  • 15 mg/kg PO once weekly (900 mg maximum)

For 3HR (daily INH + rifampin x 3 months), or 1HP (daily INH + rifapentine x 4 weeks), or INH alone (daily INH x 69 months)

  • 300 mg PO daily
Rifampina
  • NRTIs (TAF with cautionb)
  • EFV 600 mg
  • DTG, RAL (twice daily), and MVC without a strong CYP3A4 inhibitor (note: doses of these ARV drugs need to be adjusted when used with rifampin)
  • IBA, T-20

For 3HR (daily rifampin + INH x 3 months), or 4R (daily rifampin x 4 months)

  • 600 mg PO daily
  • All other ARVs
Not recommended

Rifapentinea 3HP

Weekly rifapentine + INH x 12 weeks

  • EFV 600 mg, RAL or once daily DTG
  • NRTIs (TAF with cautionb)
  • IBA, T-20
  • Weighing 32.1–49.9 kg: 750 mg PO weekly
  • Weighing ≥50.0 kg: 900 mg PO weekly
  • All other ARVs
Not recommended

Rifapentinea 1HP

Daily rifapentine + INH x 4 weeks

  • NRTIs (TAF with cautionb)
  • EFV 600 mg
  • IBA, T-20
  • Weighing <35 kg: 300 mg PO daily
  • Weighing 35–45 kg: 450 mg PO daily
  • Weighing >45 kg: 600 mg PO daily
  • All other ARVs
Not recommended
a For additional drug—drug interaction information between antiretrovirals and anti-TB drugs, see Drug-Drug Interactions in the Adult and Adolescent Antiretroviral Guidelines.

b If TAF and rifamycins are coadministered, monitor for HIV treatment efficacy. Note that FDA labeling recommends not to coadminister. See Drug-Drug Interactions in the Treatment of HIV-Related TB below and Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections table for more information

Key: ARV = antiretroviral; BIC = bictegravir; DTG = dolutegravir; EFV = efavirenz; IBA = ibalizumab; IM = intramuscular; INH = isoniazid; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; PO = oral; RAL = raltegravir; RTV = ritonavir; T-20 = enfuvirtide; TAF = tenofovir alafenamide; TB = tuberculosis

Treating TB Disease

Treating Active TB Disease in People with HIV
For Drug-Susceptible TB

Preferred Therapy

Intensive Phase (8 weeks)

  • Isoniazid plus pyridoxine plus (rifampin or rifabutin) plus pyrazinamide plus ethambutol 25–50 mg PO daily (AI)
  • If molecular or phenotypic drug susceptibility reports show sensitivity to isoniazid and rifampin, then ethambutol may be discontinued before the end of 8 weeks (AI).

Continuation Phase (for Drug-Susceptible TB)

  • Isoniazid plus pyridoxine plus (rifampin or rifabutin) 25–50 mg PO daily (AII)

Total Duration of Therapy

  • Pulmonary, drug-susceptible, uncomplicated TB: 6 months (BII)
  • Pulmonary TB and positive culture at 8 weeks of TB treatment, severe cavitary disease or disseminated extrapulmonary TB: 9 months (BII)
  • Extrapulmonary TB with TB meningitis: 9–12 months (BII)
  • Extrapulmonary TB in other sites: 6 months (BII)

Alternative Therapy (only for patients receiving an efavirenz-based ARV regimen; not recommended for extrapulmonary TB)

Intensive Phase (8 weeks)

  • Isoniazid plus pyridoxine plus rifapentine 1,200 mg plus moxifloxacin 400 mg plus pyrazinamide 25–50 mg PO daily (AI).a

Continuation Phase (9 weeks)

  • Isoniazid plus pyridoxine plus rifapentine 1,200 mg plus moxifloxacin 400 mg 25–50 mg PO daily (AI).
For Drug-Resistant TB

Empiric Therapy for Suspected Resistance to Rifamycin With or Without Resistance to Other Drugs

  • Isoniazidb plus pyrazinamide plus ethambutol plus (moxifloxacin or levofloxacin) plus (linezolid or amikacinc) (BII)

Resistant to Isoniazid

  • (Moxifloxacin or levofloxacin) plus (rifampin or rifabutin) plus ethambutol plus pyrazinamide for 6 months (BII)

Resistant to Rifamycins With or Without Other Antimycobacterial Agents

Preferred Therapy

  • For 14 days: pretomanid 200 mg plus linezolid 600 mg plus moxifloxacin 400 mg plus bedaquiline 400 PO daily, followed by
  • For 24 weeks: pretomanid 200 mg plus linezolid 600 mg plus moxifloxacin 400 mg daily, and bedaquiline 200 mg PO three times per week
  • Note: Omit moxifloxacin if resistant to fluoroquinolones (AI).

Alternative Therapy

  • An individualized regimen including based on drug susceptibility test results and clinical and microbiological responses, to include ≥5 active drugs, and with close consultation with experienced specialists (BIII).

Duration

6–24 months (see Managing Drug-Resistant TB section below for discussion of treatment duration)

Treatment of TB for Pregnant People 
  • TB therapy should not be withheld because of pregnancy (AIII).
  • Treatment of TB disease for pregnant people should be the same as for nonpregnant people, but with attention to the following considerations (AIII):
    • Monthly monitoring of liver transaminases during pregnancy and the postpartum period is recommended (BIII).
    • If pyrazinamide is not included in the initial treatment regimen, the minimum duration of TB therapy with isoniazid, rifampin, and ethambutol should be 9 months for drug-susceptible TB (AII). The decision regarding whether to include pyrazinamide in treatment regimens for a pregnant person should be made after consultation among obstetricians, TB specialists, and the patient, while considering gestational age and likely susceptibility pattern of the TB strain.
    • Fluoroquinolones are typically not recommended for pregnant people because arthropathy has been noted in immature animals exposed to fluoroquinolones in utero (CIII). Fluoroquinolones can, however, be used in pregnancy for drug-resistant TB if they are required on the basis of susceptibility testing (BII).
    • Based on data derived from studies of streptomycin and kanamycin, and the theoretical risk of ototoxicity with in utero exposure to amikacin, aminoglycosides should be avoided during pregnancy, if possible (AIII).
TB-Associated IRIS

Preventing Paradoxical TB-IRIS

  • In high-risk patients (i.e., starting ART within 30 days after TB treatment initiation and a CD4 count ≤100/mm3) who are responding well to TB therapy and who do not have rifampin resistance, Kaposi sarcoma, or active hepatitis B (BI): prednisone 40 mg/day for 2 weeks, then 20 mg/day for 2 weeks

Managing Paradoxical TB-IRIS

  • Paradoxical reaction/IRIS that is not severe may be treated symptomatically (CIII).
  • For moderately severe paradoxical TB-IRIS, use of prednisone is recommended (AI).
  • In patients on a rifampin-based regimen: prednisone 1.5 mg/kg/day for 2 weeks, then 0.75 mg/kg/day for 2 weeks
  • In patients on a rifabutin plus boosted PI-based regimen: prednisone 1.0 mg/kg/day for 2 weeks, then 0.5 mg/kg/day for 2 weeks
  • Taper over 4 weeks (or longer) based on clinical symptoms; a more gradual tapering schedule over 2 to 3 months is recommended for patients whose signs and symptoms have not improved or have worsened due to tapering (BIII).
Other Considerations in TB Management
  • Adjunctive corticosteroid is recommended for patients with HIV-related TB involving the CNS (AII).
  • Dexamethasone has been used for CNS disease with the following dosing schedule: 0.3–0.4 mg/kg/day for 2–4 weeks, then taper by 0.1 mg/kg per week until 0.1 mg/kg, then 4 mg per day and taper by 1 mg/week; total duration of 12 weeksd
  • Despite the potential of drug–drug interactions, rifamycins remain the most potent TB drug and should remain as part of the TB regimen, unless a rifamycin-resistant isolate is detected or the patient has a severe adverse effect that is likely due to the rifamycin (please refer to the Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB below and the Tuberculosis/HIV Coinfection section of the Adult and Adolescent Antiretroviral Guidelines for dosing recommendations involving concomitant use of rifampin or rifabutin and different ARV drugs).
  • Intermittent rifamycin use can result in the development of resistance in patients with HIV and is not recommended (AI).
a This regimen was not studied and is not recommended for people who are pregnant, breastfeeding, <40kg, or who have most types of extrapulmonary TB (other than pleural TB or lymphadenitis).

b Many patients with rifampin resistance also have resistance to isoniazid. Susceptibility should be confirmed in any patient with rifampin resistance to determine if isoniazid can be included in the treatment regimen.

c Given the risk of ototoxicity and nephrotoxicity with aminoglycosides, use of amikacin should generally be restricted to bridging regimens, while awaiting availability of less toxic medications and/or results of drug-susceptibility testing.

d At doses above 16 mg, dexamethasone is a CYP3A4 inducer and can decrease certain ARVs that are substrates of CYP3A4 (e.g., DOR, RPV, and protease inhibitors). Consultation with a pharmacist is recommended.

Key: ARV = antiretroviral; CNS = central nervous system; DOT = directly observed therapy; IRIS = immune reconstitution inflammatory syndrome; LTBI = latent tuberculosis infection; PI = protease inhibitor; PO = orally
Dosing Recommendations for Use of ARV and Anti-TB Drugs for Treatment of Active Drug Sensitive TB
TB DrugARV DrugsDaily Dose
IsoniazidAll ARVs5 mg/kg (usual dose 300 mg)
Use INH with pyridoxine 25–50 mg PO daily
Rifampina,b
  • NRTIs (use TAF with cautionc)
  • EFV 600 mg
  • DTG, RAL (twice daily), MVC without a strong CYP3A4 inhibitor (note: doses of these ARVs need to be adjusted when used with rifampin)
  • IBA, T-20
10 mg/kg (usual dose 600 mg)
  • DOR, ETR, EFV 400 mg, NVP, RPV (PO)
  • BIC, EVG/c, RAL (daily)
  • CAB/RPV (IM/PO)
  • HIV PIs
  • LEN (SC/PO), FTR, MVC with a strong CYP3A4 inhibitor
Not recommended
Rifabutina
  • NRTIs (use TAF with cautionc)
  • ETR without boosted PIs
  • DOR and RPV (PO) (note: doses need to be adjusted when used with rifabutin)
  • DTG, RAL
  • MVC without a strong CYP3A4 inhibitor
  • IBA, T-20, FTR
5 mg/kg (usual dose 300 mg)
  • PIs with RTV MVC with a strong CYP3A4 inhibitor
150 mg dailye
  • EFV
450–600 mg
  • ETR with boosted PIs
  • BIC, EVG/c
  • CAB/RPV (IM/PO)
  • PIs with COBI
  • LEN (SC/PO)
Not recommended
Rifapentine
  • EFV
  • NRTIs (use TAF with cautionc)
1,200 mg/day for people weighing ≥40 kg
  • All other ARVs
Not recommended
PyrazinamideAll ARVs

Weight-based dosing

  • 40–55 kg: 1,000 mg
  • 56–75 kg: 1,500 mg
  • 76–90 kg: 2,000 mg
  • >90 kg: 2,000 mgf
EthambutolAll ARVs

Weight-based dosing

  • 40–55 kg: 800 mg
  • 56–75 kg: 1,200 mg
  • 76–90 kg: 1,600 mg
  • >90 kg: 1,600 mgf
Moxifloxacin
  • All ARVs
  • 400 mg daily for those weighing ≥40 kg

a For more detailed guidelines on use of different ARV drugs with rifamycin, clinicians should refer to the Drug–Drug Interactions section of the Adult and Adolescent Antiretroviral Guidelines.

b Higher doses may be needed in the treatment of TB meningitis. Expert consultation is advised.

c If TAF and rifamycins are coadministered, monitor for HIV treatment efficacy. Note that FDA labeling recommends not to coadminister. See text below and Table 4 for more information.

e Acquired rifamycin resistance has been reported in patients with inadequate rifabutin levels while on 150 mg three times per week dosing together with RTV-boosted PIs. May consider therapeutic drug monitoring (TDM) when rifabutin is used with an RTV-boosted PI and adjust dose accordingly.

f Monitor for therapeutic response and consider TDM to assure dosage adequacy in patients weighing >90 kg.

Note: For drug-drug interaction information between antiretrovirals and anti-TB drugs for treatment of drug-resistant TB, see the Adult and Adolescent Antiretroviral Guidelines. 

Key: ARV = antiretroviral; BIC = bictegravir; BID = twice a day; CAB = cabotegravir; COBI = cobicistat; DOR = doravirine; DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; EVG/c = elvitegravir/cobicistat; FTR = fostemsavir; IBA = ibalizumab; IM = intramuscular; INH = isoniazid; LEN = lenacapavir; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PO = oral; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SC = subcutaneous; T-20 = enfuvirtide; TAF = tenofovir alafenamide; TB = tuberculosis; TDM = Therapeutic Drug Monitoring

Download Guidelines